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Abstract 
Objective: To document the patient characteristics, primary care and hospital 
management and QoL in patients with intermittent claudication in the United 
Kingdom. Also to determine the appropriate use of prophylactic therapy, to 
determine markers of high and low risk and to suggest approaches to optimise 
the management of peripheral arterial disease. 
Methods: 474 patients were recruited from 23 centres across the United 
Kingdom. Data was collected at baseline and at six months and risk factors 
profile was analysed. 
Results: Symptomatic disease is more prevalent in men and those above 60. A 
high proportion of patients were hypertensive and control of blood pressure was 
not optimal. Use of antiplatelet agents and lipid lowering therapy was less than 
satisfactory though it improved following hospital referral. Life style modification 
advice was patchy and not uniform and intensive support for such programmes 
was lacking. Majority of patients improved not only on clinical parameters but 
also their QoL over a six month period. 35% underwent peripheral imaging and 
7.8% had an interventional procedure. 14% had a vascular event over six 
months. Low ABPI, high systolic pressure and prior CHD were significantly 
associated with development of all vascular events. 
Conclusions: Use of appropriate therapy to reduce the risk factor profile is less 
than optimal. There is a need for uniform national guidelines for appropriate 
management of peripheral arterial disease patients in the United Kingdom. 
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Chapter 1 
Risk factor profile of patients with peripheral_arterial disease and 
its current management: Review of the literature. 
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1.1 Introduction 
Peripheral arterial disease (PAD) is a major public health problem. It is a 
hallmark of systemic pathology that not only affects the peripheral arterial system 
but also the coronary, cerebral and renal arteries. 
The development of atherosclerosis is linked with a number of risk factors. 
Modification of these risk factors might reduce the development of PAD and in 
turn improve cardiovascular morbidity and overall mortality. However the 
management of patients with identical PAD varies widely between centres in the 
United Kingdom. In order to establish a national treatment strategy for PAD it is 
important to know the magnitude of the problem together with the likely outcomes 
in patients with differing severity of PAD. Hence, there is a need to establish the 
distribution patterns of PAD risk factors and further stratification of these in 
relation to progression of the disease process. This will help in developing a 
uniform action plan for the management of PAD. 
The most common clinical presentation of PAD is intermittent claudication (IC). 
Assessment of claudicants can help to provide the detail of risk factors involved 
and their impact on the progression of disease over a period of time. 
1.2 Intermiftent Claudication 
IC, the most frequent symptom complex of PAD, is characterised by calf, thigh or 
buttock pain and weakness brought on by walking, with the disappearance of the 
symptoms following a brief rest. 
1.2.1. Clinical assessment 
A good history and clinical examination forms the basis of clinical assessment in 
suspected cases of IC. Palpation of the peripheral pulses is a less sensitive 
measure of PAD [1-3]. Diagnostic accuracy may be improved by using a 
standard questionnaire such as the Edinburgh Claudication Questionnaire (ECQ) 
or the World Health Organisation / Rose questionnaire, though false-positive 
rates of up to 44% and false-negative rates of up to 19% have been reported 
after verification by non-invasive tests [4-7] . 
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1.2.2. Ankle: brachial pressure index (ABPI) 
The most useful non-invasive test for the diagnosis of PAD is the ankle: brachial 
pressure index (ratio of best systolic blood pressure in dorsalis pedis or the 
anterior tibial arteries in the lower limb to systolic blood pressure in the brachial 
artery). A resting ABPI of 0.90 is considered to be 95% sensitive in detecting 
PAD and almost 100% specific in identifying apparently healthy individuals [8- 
14]. It may however be unreliable in case of diabetics due to calcification of the 
peripheral vessels resulting in incompressibility. An ABPI of greater than 0.90 is 
considered normal; 0.7 to 0.89 is considered mild disease; 0.5 to 0.69, moderate 
disease; and less than 0.5, severe disease [15]. A resting ABPI of less than 0.9 is 
usually associated with a 50% or greater vessel stenosis [16]. The Edinburgh 
Artery Study has shown an association between ABPI and severity of disease in 
the general population. 
1.3 Epidemiology 
PAD can broadly be divided into two groups, 
i) symptomatic, presenting mainly as IC, and 
ii) asymptomatic 
1.3.1. Incidence of Intermittent Claudication 
The number of new patients with PAD seen by a U. K. general practitioner per 
annum appears similar to the number of new cases of M. 1 or stroke seen [19]. 
However, many patients with IC are elderly and may consider their symptoms to 
be part of growing old and not consult a doctor. One half of all PAD patients older 
than 55 years are asymptomatic [18]. Of the symptomatic patients, approximately 
80% experience IC, and 20% have critical limb ischaernia [19]. The proportion 
that consults their general practitioner varies from 10% in the inner city to 50% in 
rural communities [20,21]. 
1.3.2. Prevalence of PAD 
The prevalence of PAD differs depending on the study population and the 
diagnostic methods used [19,21,22-28] . Even when the same diagnostic 
criteria are used, this can result in different prevalence rates, depending on the 
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age, sex, and geographic location of the population studied (Tablel. 1). Thus, the 
reported prevalence rates for IC using the Rose questionnaire vary from 0.4% to 
14.4% [22]. The PARTNERS programme found the prevalence of PAD in the 
population of patients older than 70 years and/or older than 50 years with co- 
morbidities (e. g., smoking and concomitant diabetes) to be 29%. Of the number 
of cases of PAD detected, as many as 44% were newly diagnosed with the use 
of the ABPI technique [29]. 
The prevalence of PAD increases rapidly with age, as does the hospital 
admissions rate [19,25,27]. In the male population the prevalence of IC is 3 -. 
6% around the age of 60 years. For the UK, the Edinburgh Artery Study has 
shown the prevalence to be 4.5% between 55 and 74 years of age [25]. Varied 
results relating to sex distribution have been produced by population based 
studies. Overall PAD has been shown to be higher in the male population for a 
given age and this ratio has ranged from 1 to 8 [30]. 
1.3.3. Prevalence of asymptomatic disease 
The prevalence of asymptomatic disease can be estimated only by using non- 
invasive techniques, like the measurement of ankle systolic pressures [31-33] 
and duplex scanning, though the later has not been used widely in 
epidemiological surveys. The reported prevalence of asymptomatic disease 
ranges from 0.9% to 22% with the ratio of symptomatic to asymptomatic disease 
in individual studies varying between 1: 0.9 to 1: 6.0 [19,23,31-38]. 
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Study Location 
Hughson et al, England 
1978 ý201 
De Backer et al, Belgium 
1979 ý341 
Reunanen et al, Finland 
1982 [221 
Stoffers et al, Netherlands 
1991 1191 
Sample Age Prevalence 
Size N 
1716 45-69 2.2 
8252 40 -49 
50-59 
5738 30 -39 
40-49 
50-59 
3654 45 -54 
55-64 
65-74 
Fowkes et al, Scotland 1592 55-74 
1991 (231 
Smith et al, 1991 Scotland 10042 40-59 
0.8 
2.3 
0.9 
1.6 
4.6 
0.6 
2.5 
8.8 
4.5 
1.1 
[241 
Novo et al, 1992 Palermo 1558 40-49 4.7 
[281 
50-59 9.2 
Aronow et al 2002 New York 3624 80+/-8 32 
[251 USA 81 +/-8 26 
Murabito et al Massachusetts 3313 > 40 3.9 
2002 [39] USA mean 59 3.3 
Fowler et al 2002 Perth, 4470 65-83 15.6 
[271 Australia. 
Selvin et al 2004 Baltimore, USA 2174 40+ 4.3 
[40] 70+ 14.5 
ol PA 1) ill large popidelliol'I hasedsludies 
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1.4. Risk Factors in PAD 
The risk factors for developing PAD are similar to those for other atherosclerotic 
diseases. The influence of age and sex in the incidence and prevalence of IC has 
already been considered. The following risk factors are associated with 
development of PAD: 
1.4.1. Smoking 
All epidemiological studies of PAD have confirmed that cigarette smoking is a 
strong risk factor for the development of IC [20,22-24,41-48]. Symptomatic 
PAD is three times more common among smokers than non-smokers [49]. 
Epidemiological evidence has suggested that the association between smoking 
and PAD may be even stronger than that between smoking and coronary artery 
disease (CAD) [50-53]. In the Framingham study, the risk at all ages was almost 
double for PAD as compared to CAD [43]. The diagnosis of PAD is made up to a 
decade earlier in smokers than in non-smokers [46,48,51]. The severity of PAD 
tends to increase with the number of cigarettes smoked [43,52-57] and heavy 
smokers have a fourfold risk of developing IC [43] . 
Smoking is the most significant risk factor that is associated with disease 
progression. Cronenwett et al found that patients with IC who had smoked at 
least 40 pack-years required reconstructive vascular surgery over three times 
more frequently than those who had smoked less [58]. A major amputation rate 
of 6-11% has been reported in patients with IC who smoke compared with no 
major amputations in non-smoking claudicants [30,59,60]. The 5-year mortality 
rate for patients with IC who continue to smoke is 40% to 50% [60]. Smoking 
cessation has been associated with a rapid decline in the incidence of IC and the 
risk of IC for ex-smokers one year after quitting is approximately the same as that 
for non-smokers [55,56]. However, the Edinburgh artery study found that the 
relative risk of IC was 3.7 in smokers compared with 3.0 in ex-smokers of more 
than 5 years [48]. 
1.4.2. Diabetes mellitus and impaired glucose tolerance 
The association between diabetes mellitus and the development of PAD is now 
well established [43-45,49,61-65]. IC is about twice as common amongst 
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diabetic patients as among non-diabetic patients [30]. Insulin resistance seems to 
play a key role [64]. 
PAD in patients with diabetes is more aggressive, with early large vessel 
involvement coupled with microangiopathy. Diabetic patients with IC have a 35% 
risk of acute ischaernia and a 21 % risk of major amputation, compared with 19% 
and 3%, respectively, in nondiabetic claudicant patients [65]. Similar results have 
been reported by Dormandy and Jelnes [21,66]. 
1.4.3. Hypertension 
Hypertension increases PAD risk by two to three fold and is particularly 
associated with the development of severe disease [39]. The Framingham study 
showed that hypertension carried a 2.5-fold age-adjusted risk in men and a 3.9- 
fold age-adjusted risk in women [43]. Similar evidence has been produced by the 
Edinburgh and the Basle studies [48,61] though the Whitehall and the Finnish 
studies have found no association between the two [22,67]. 
Hypertension may delay the onset of IC by elevating the central perfusion 
pressure. As a result newly diagnosed hypertensive may develop IC on initiation 
of antihypertensive therapy. Disease progression and deterioration has been 
related with higher systolic arterial pressure [66]. 
1.4.4. Hyperlipidaemia 
Total cholesterol is a powerful independent risk factor for the development of 
PAD [43,52]. In the Framingham study, a fasting cholesterol level greater than 7 
mmol/L was associated with a doubling incidence of IC [45]. It appears that the 
ratio of total to high-density lipoprotein (HDL) cholesterol is a better predictor of 
occurrence of arterial disease [60]. Treatment of hyperlipidaemia reduces both 
the progression of PAD and the incidence of IC [68-70]. Interestingly postprandial 
hyperlipaemia has been reported in patients with normolipaernic PAD [71] and an 
association between PAD and hypertriglyceridaernia has also been reported [21, 
20,22,43]. Hypertriglyceridemia may be associated with the progression and 
systemic complications of PAD [72]. Recently, Lipoprotein (a) (Lp[a]) has been 
reported to be a significant independent PAD risk factor [73]. 
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1.4.5. Hyperhomocysteinaemia 
Hyperhomocysteinaernia has been described to be an independent risk factor for 
the development of atherosclerotic lesions in peripheral arteries [74-76]. Raised 
homocysteine levels have been detected in 28-30% of patients with premature 
PAD [77,78]. Among vascular patients, the incidence of hyperhomocysteinaemia 
may be as high as 60% compared with 1% in the general population [79,80] and 
has been observed as a stronger risk factor for PAD than coronary artery disease 
(CAD) [81]. However, Darius et al have found that elevated HC is only slightly 
more related to PAD than to CAD and cerebrovascular disease (CVD). After 
adjustment for known risk factors, they suggested that the effect size is small, 
and an association can no longer be observed between homocysteine and CAD 
and CVD [82]. 
1.4.6. Fibrinogen 
High fibrinogen levels pose a high thrombotic risk. An increased fibrinogen level 
has been found to be associated with increased risk of PAD and also indicates 
an increased risk for poor outcome, particularly for fatal cardiovascular 
complications [20,83-85]. A positive correlation has also been seen between 
elevated fibrinogen and asymptornatic PAD and to the future onset of PAD [86, 
87]. 
1.4.7. Miscellaneous factors 
Patients with IC have raised haematocrit levels and this may be a predictor of 
future graft occlusion [88-90]. This increase in haematocrit may be attributable to 
an association with smoking. Similarly, high plasminogen levels and raised mean 
corpuscular volume have also been found to be associated with PAD [91,92]. 
Patients with PAD have also an altered coagulation state [93,94], and their 
platelets show a tendency to increased aggregation and thrombus formation [95- 
97]. Recently, elevated D-dimers and C reactive protein (CRP) have also been 
associated with PAD [98,99]. However it is unclear whether these factors are 
themselves involved in the pathophysiology of functional impairment or whether 
they are simply sensitive markers of the extent of systemic atherosclerosis. Other 
markers like serum amyloid A (SAA), the proinflammatory cytokine interleukin 6 
(IL-6), the active and total fractions of the anti-inflammatory cytokine transforming 
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growth factor-beta (TGF-beta), the macrophage activation marker neopterin and 
the infection marker procalcitonin, constitute an inflammatory signature of 
advanced atherosclerosis and are correlated with the extent of disease [100]. 
These do not provide discriminatory diagnostic power over and above 
established risk factors. 
1.4.8. Coexisting risk factors 
The coexistence of risk factors increases the risk of PAD quite significantly. The 
Basle study reported that the relative risk increased from 2.3 in cigarette smokers 
alone to 3.3 in smokers with diabetes, and to 6.3 in smokers with systolic 
hypertension and diabetes [101]. The Framingham study reported that male sex, 
age and smoking were associated with a 1.5-fold increased risk for IC. Diabetes 
and hypertension conferred a >2-fold increased risk and CAD nearly tripled the 
risk for IC [45]. The probability of IC is increased in the presence of risk factors 
and smoking dramatically escalates it at any given risk factor level. 
1.4.9. Genetic risk 
Unlike CAD and CVD, a positive family history has not been confirmed as a 
significant risk factor in the development of PAD [83,102,103]. Individual risk 
factors may be elevated secondary to genetic predisposition. There seems to be 
some role of mutations in the genes coding for fibrinogen, Factor V and 
m ethyle n etetra hyd rofo late reductase and PAD [104]. Plasma fibrinogen levels 
are under substantial genetic control, as genetic polymorphisms account for 
some 20 -51% of variations in plasma fibrinogen levels [105]. 
1.4.10. Protective factors 
Regular exercise and moderate alcohol intake have been shown to be positive 
protective factors for the development of IC [106,107]. Increased level of high- 
density lipoproteins is also considered as a positive predictive factor in CAD but 
its role in such a capacity for PAD has yet to be substantiated. Clearly, the 
absence of a risk factor is protective in itself. 
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1.5 Co-existing vascular diseases 
As mentioned previously, PAD is a marker of diffuse atherosclerosis, and is not 
surprising that it frequently occurs in conjunction with CAD and CVD. 
Epiderniologic and natural history studies have determined that PAD confers a 
high risk of fatal and nonfatal cardiovascular ischaernic events [30,60,108-111 ]. 
It is associated with a very high risk of myocardial infarction (MI), stroke, and 
other thromboembolic events, increased mortality, diminution of quality of life and 
a shortened five-year survival [21,36,108,112,113]. 
The calculated prevalence rate of CAD in patients with claudication is dependent 
upon the diagnostic criteria used [21,45,109,114-124]. It ranges from 35% 
(questionnaire based - mainly symptomatic) to 90% (coronary angiograrn - 
combined symptomatic and asymptomatic) [21,114]. A proportion of these 
patients may be asymptomatic if exercise is severely limited by claudication. 
Asymptomatic patients like the symptomatic group, are also at increased risk of 
MI, stroke and vascular death [35,52]. Similarly individuals with CAD are more 
likely to suffer from PAD than the non-CAD individuals [22,45]. However, the 
link between PAD and CVD seems to be weaker than that with CAD [109]. 
Although approximately half of all patients with IC have CAD, a much lower 
proportion have demonstrable CVD [21,106,109,125]. Imaging techniques like 
duplex scanning reveal carotid disease in 26 - 50% of patients with IC [126- 
129]. Overall the current evidence suggests that approximately 40% of patients 
with CAD or CVD suffer from PAD. Similarly 60% of the patients with PAD have 
coronary or cerebrovascular disease [50,130]. 
1.6. Natural history & progression of intermittent claudication 
The progression of PAD can be considered in terms of the systemic outcomes 
like CAD and CVD events, and the local progression of disease in the limbs. 
1.6.1. Local Disease 
1.6.1.1. Improvement orstabilisation 
In a majority of cases the clinical course of IC is benign [131]. Only a quarter of 
patients with IC ever deteriorate significantly [132]. The Basle study documented 
angiographic progression of the disease in 63% of patients 5 years after the 
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initial diagnosis [106]. Of those who had survived for 5 years after the diagnosis, 
66% still had no limiting IC. This symptomatic stabilisation may be attributed to: 
(i) the development of collaterals, 
(ii) metabolic adaptation of ischaemic muscle by an increase in aerobic 
enzyme content, 
(iii) increase in capillary density, or 
(iv) altered gait of the patient to favour non-ischaemic muscle groups. 
1.6.1.2. Worsening claudication 
The highest risk of significant deterioration has been noted during the first year 
after diagnosis (7%-9%) compared with 2% to 3% per annurn thereafter [66, 
132]. Dormandy has shown approximately 6% deterioration in exercise tolerance 
over the first year in non-surgical hospital patients [133]. Hospital-based series 
tend to identify patients with IC who have more severe disease or whose 
symptoms are progressing. A resting ABPI of 0.5 or less has been postulated to 
be the most significant predictor of limb deterioration [133]. 
Need for intervention 
In general, the indications for intervention are a significant deterioration in ability 
to carry out daily routines, increasing disability and increasing pain. Young 
patients with relatively better exercise tolerance than the elderly, whose 
livelihood is at risk because of inadequate performance of ambulant duties, are 
also good candidates for intervention. The frequency of local intervention has 
varied widely from 3% to 22% [134,135]. The existing data suggest that only one 
fourth of all patients with IC deteriorate progressively, with an intervention rate of 
approximately 5% over 5 years for either severe claudication or deterioration to 
critical limb ischemia [30]. It is important to note here that a group of patients, 
who otherwise would be candidate for intervention, may not be considered for 
one because of poor card io-respiratory status or impaired cognition. 
1.6.1.4. Amputation 
Major amputation is a relatively rare outcome of claudication. Only 1.0 - 3.3% of 
patients with IC need a major amputation over a 5-year period [134,136]* The 
25 
Basle and Framingham studies report a major amputation rate of around 2% in 
claudicants [60,101 ]. Earlier studies have reported an amputation rate of 7% at 5 
years [115,116]. The improved recent results reflect a successful intervention 
rather than the true natural progression of the disease. 
1.6.2. Progression of Systemic Atherosclerosis 
Patients with either asymptornatic or symptomatic PAD have a significantly 
increased risk of stroke, MI, and cardiovascular death as discussed in section 
1.5. PAD should therefore be viewed as a sign of potentially diffuse and 
significant arterial disease. The Edinburgh Artery study has shown that patients 
with IC have a significantly increased risk of angina (relative risk, 2.31) whereas 
asymptornatic PAD patients have a slightly increased risk of MI and stroke [139]. 
Recent reports show a1- 3% annual incidence of nonfatal MI in these patients 
[133,136]- The Edinburgh group has also reported an incidence of 8.2% of MI, 
9.6% of angina and 6.8% of CVD during a follow up of five years [137]. There 
seems to be a general agreement that between 2% to 4% of patients with IC 
have a nonfatal cardiovascular event within the first year [30]. 
1.6.3. Mortality 
The mortality rate of the claudicant population is on an average 2.5 times that of 
nonclaudicants [133]. A claudicant's life expectancy is estimated to be 10 years 
less than a control population [132]. PAD is associated with diminished QoL and 
a shortened five-year survival [23,36,108,112,113]. CAD is by far the most 
common cause of death among patients with PAD (40%-60%), while CVD 
accounts for 10-20% [138,139]. Another 10% of PAD patients die due to other 
vascular causes like, aortic aneurysm. Thus, 20-30% of patients with PAD die of 
non-cardiovascular causes. The 5-, 10-, and 15-year mortality rates from all 
causes are approximately 30%, 50%, and 70%, respectively [30]. This 
emphasises that the real danger for the patient with IC is not the local disease 
itself but cardiac and cerebral complications or death. Claudicant patients with 
coronary ischaernia have survival curves similar to non-claudicants who had 
survived an MI [59,114]. 
Smoking [140-142], diabetes [66,116-119,123,133,140], hypertension [66,115, 
133], white cell count [133,141], asymptomatic carotid disease [1421, 
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hypertriglyceridemia [72] and fibrinogen [141,143] have all been reported as 
predictors of mortality. Smoking increases mortality rates among patients with IC 
by 1.5 to 3.0 [7]. Interestingly, diabetes seems to be less of a mortality risk than 
the progression of local disease in the legs. ABPI remains the most powerful tool 
for the prediction of all-cause mortality in the PAD population [144]. 
1.7. Interventions to reduce risk factor profile 
Since individuals with PAD are at markedly increased risk of cardiovascular 
ischaernic events, early identification of this population and more aggressive 
medical interventions may potentially improve both morbidity and survival. 
Despite the known benefits of antiplatelet therapy and treatment of hypertension 
and hyperlipidaernia in reducing ischaernic event rates, PAD patients are less 
intensively treated than patients with CAD or CVD [29,30,145]. As discussed 
above vascular intervention is needed in a minority and most claudicants can be 
managed conservatively [134,135]. Aggressive risk factor management is known 
to result in reduction of vascular events in patients with previous MI. Therefore it 
seems probable that early recognition and diagnosis of PAD combined with its 
appropriate life style modification and risk factor management may reduce overall 
risk of further adverse vascular events. 
1.7.1.1. Life style modification 
Smoking cessation 
All patients with PAD should be strongly and repeatedly advised to stop smoking 
[7,58,59,140-142]. Special programmes can enhance smoking cessation, 
though motivation remains the cornerstone. Counselling can give much-needed 
support and nicotine replacement therapy or Bupropion (Zyban -a 
norepinephrine, serotonin and dopamine neuronal uptake inhibitor) may help to 
reduce craving [146]. Nicotine replacement substitutes treat the very difficult 
withdrawal symptoms and cravings that 70% to 90% of smokers which is the 
main reason for not giving up cigarettes. By using a nicotine substitute, a 
smoker's withdrawal symptoms are reduced. Nicotine replacement therapy (NRT) 
gives a small dose of nicotime that helps to cut down the urge to use tobacco. 
Nicotine chewing gum, lozenges and patches are available over the counter. This 
therapy can also be prescribed as nasal sprays and inhalers. National Institute of 
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Clinical Excellence has recommended NRT and bupropion for smokers who have 
expressed a desire to quit smoking. NRT or bupropion should normally only be 
prescribed as part of an abstinent-contingent treatment, in which the smoker 
makes a commitment to stop smoking on or before a particular date (target stop 
date). 
Success of smoking cessation is dependent on patient motivation and available 
support. Smokers should be offered advice and encouragement to aid their 
attempt to quit. Active intervention can achieve an abstinence rate of 16% at one 
year [147]. NRT increases the odds of smoking cessation by approximately 1.5 - 
2 fold [148]. This appears to be largely independent of the intensity of any 
additional support for smoking cessation. Standard self-help materials may 
increase quit rates compared to no intervention, but the effect is likely to be 
small. Telephone and internet based quitlines and family and friends support can 
be helpful in smoking cessation programme. Group behavioural therapy has 
been reported to be more successful than the self help approach [149,150]. 
Several other strategies like hypnosis, acupuncture, filters and smoking 
deterrents have been employed with very little success [151,152]. 
Exercise 
Trials have clearly demonstrated that walking capacity is increased by exercise 
training in patients with claudication [153-156]. Supervised exercise conducted 
for more than three months has shown increase in treadmill exercise 
performance [157-162). Ameta-analysis of structured exercise studies reported 
an average increase of 179% in initial claudication distance and a 122% 
increase in absolute walking distance on the treadmill [163]. This benefit may be 
lost if exercise is stopped. The predictors of response to the training programme 
include a high level of claudication pain during the training sessions and 6 
months or longer of formal training and walking exercise as compared to other 
training modalities. Exercise rehabilitation itself has been associated with a 
minimal morbidity and mortality [164]. Peak exercise performance and peak 
oxygen consumption improves with treadmill training, the heart rate decreases 
along with an improvement of ventilation and oxygen consumption at a given 
sub-maximal workload [165,166]. Efficient glucose metabolism, a reduction in 
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cholesterol and triglyceride concentrations and enhanced smoking cessation 
have also been reported with regular exercise [167]. It also has a positive impact 
on the QoL as it improves the functional status of the claudicant [168]. 
1.7.1.3. Weight control 
Overweight patients with IC may benefit from reducing weight in terms of 
claudication distance by reducing work-load. Obesity is a recognised risk factor 
of most fatal and nonfatal cardiovascular events. Abdominal fat distribution, but 
not total body fat, has been associated with PAD, independently of concurrent 
cardiovascular risk factors [169]. 
1.7.2. Hyperlipidaemia 
Analysis of data from several large trials suggests that rising vascular event rates 
correlate closely with increasing LDL cholesterol levels [170-172]. Elevated LDL 
cholesterol and triglyceride levels and low HDL cholesterol levels are of key 
importance in the development of PAD [48,60,69,72,171,172]. Recent studies 
have supported the role of lipid modification in stabilisation or regression of 
arterial atherosclerosis [69,70,173-175]. 
The Scandinavian simvastatin (4S) study has shown that simvastatin reduces the 
risk of development or worsening of claudication by 38% [1]. The Heart 
Protection Study (HPS) with over 20000 participants aged 40-80 years, has also 
established the beneficial effect of statin therapy in several high risk populations 
[176]. Overall there was a highly significant 18% proportional reduction in the 
coronary death rate (5-7% vs. 6.9%; p=0-0005) and a marginally significant 
reduction in other vascular deaths (1-9% vs2-2%; p=0-07) in patients taking 
simvastatin. It concluded that five years of 40mg once daily simvastatin would 
prevent about 70 -100 people per 1000 from suffering at least one of the major 
vascular events (including myocardial infarction, stroke and either coronary or 
peripheral arterial revascularisation). There was a significant reduction of 
cardiovascular events in the PAD subgroup (p<0.0001) and the need for 
peripheral revascularisation was also reduced. The benefit obtained with use of 
simvastatin in this study was across the board irrespective of cholesterol levels. 
A1 mmol/L reduction in LDL cholesterol from about 4 mmol/L to 3 mmol/L 
reduced the risk of major vascular events by about one-quarter, and so too did 
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reducing it from about 3 mmol/L to 2 mmol/L. Perhaps this can be explainied by a 
pleotropic effect of statin therapy which is protective in nature and is independent 
of the total cholesterol and LDL levels. This reduction of cardiovascular events 
was to a greater extent than can be explained from effects of statins on serum 
inflammatory markers especially C-reactive protein. A recent meta-analysis has 
reported a statistically significant reduction of C-reactive protein levels by all 
statins [177]. This suggests a statin-mediated anti-inflammatory effect that 
perhaps contributes to the ability of statins to reduce risk for cardiovascular 
disease. 4S and Mondillo et al have also shown improved walking performance 
and claudication symptoms in PAD patients with the use of simvastatin [1,178]. 
Similar results have been reported for other statins (157). Atorvastatin improves 
pain-free walking distance and community-based physical activity in patients with 
IC [176]. McDermott et al have recently shown that statin use is associated with 
superior leg functioning compared with no statin use, independent of cholesterol 
levels and other potential confounders [179]. Wilbert et al have observed that 
patients with PAD and a serum LDL cholesterol of >3.5mmol/L have a lower 
incidence of new coronary events if they were treated with statins as compared 
to those without (48%vs73%) [180]. Any patient with occlusive vascular disease 
be it coronary, cerebrovascular or PAD and baseline total cholesterol above 
3.5mmol/I without contraindications should probably now receive a statin. 
Generally patients with a high cholesterol and LDL levels should be advised 
dietary modification [72]. Dietary advice may be effective in treating 
hype rtrig lyce rid aem ia, which has been shown to enhance the progression of 
disease process [181]. Non-statin lipid lowering agents can also be employed in 
various clinical scenarios other than the intolerance and side effects of the statin 
therapy. Niacin may have a role in patients with low HDL cholesterol. Patients 
with low HDL and elevated triglyceride levels in which diet therapy has failed may 
benefit from fibrates [30]. 
Most of the studies looking at lipid lowering drugs have generally been conducted 
in CAD patients with subgroup analysis of PAD patients. This subgroup has been 
less intensely treated as compared to CAD [182]. Additional data is however 
required to establish the effects of statins and other lipid lowering therapy on 
development of future vascular events in PAD population. 
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Lp(a), a lipoprotein fraction has been shown to be an independent risk factor for 
PAD [73,173]. Unfortunately, there are no specific treatments for elevated LP(a) 
levels except to aggressively treat abnormalities in other lipid fractions. 
1.7.3. Hypertension 
Hypertension is associated with the development of atherosclerosis, particularly 
in the coronary and cerebral circulations. These patients also have a two- to 
threefold increased risk of IC [4,45,183,184]. The effect of hypertension 
treatment on the natural history of peripheral atherosclerosis has yet to be 
evaluated. The evidence for the use of various anti-hypertensive drug classes in 
PAD is poor, and it is unknown whether significant benefit or risk accrues from 
their use. General consensus still supports the management of hypertension in 
PAD and the drug treatment of hypertension can follow the same guidelines as in 
patients without PAD [30]. A large decrease in systemic blood pressure in a 
group of patients may worsen the claudication [185]. Nevertheless, there is still a 
risk reduction of stroke, MI, and cardiovascular death by antihypertensives in 
PAD [183]. Mehler et al have reported that intensive blood pressure lowering to 
a mean of 128/75 mm Hg resulted in a marked reduction in cardiovascular 
events in PAD patients with diabetes [184]. 
Patients with PAD are at increased risk of renal hypertension, secondary to renal 
arterial atherosclerosis. Plasma creatinine level should therefore be measured 
prior to institution of hypertensive drug therapy, probably with Angiotensin 
converting enzyme (ACE) inhibitors. 
Use of beta-blockers has not been shown to adversely affect mild to moderate 
claudication [186,187]. ACE inhibitors have shown to improve endothelial 
function, cardiac and vascular remodelling, retard the anatomic progression of 
atherosclerosis, and reduce the risk of MI, stroke, and cardiovascular death 
[1881. In HOPE (Heart Outcome Prevention Evaluation) study subgroup analysis 
of 4051 patients with PAD from a total of 9297, showed ramipril, an ACE 
inhibitor, significantly reduced the rate of cardiovascular death, myocardial 
infarction, and stroke in a broad range of patients at high risk of cardiovascular 
death [relative risk [RR] = 0.78; 95% Cl, 0.70 to 0.86; P<0.001) [189]. These 
effects could not be explained due to the antihypertensive effect of ramipril alone. 
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1.7.4. Diabetes mellitus 
Diabetes mellitus has a strong association with lower-extremity arterial disease 
and its progression [48,49,129,190-192]. The United Kingdom Prospective 
Diabetes Study (UKPDS) has shown a significant reduction in any diabetes 
macrovascular (myocardial infarction, stroke, amputation including death from 
peripheral vascular disease) and microvascular (predominantly retinal photo- 
coagulation, neuropathy and nrephropathy) disease end points, following strict 
blood glucose control [192]. Metformin has also been associated with a reduction 
in diabetic complications and all-cause mortality [193]. It is recommended that 
patients with diabetes and PAD should have aggressive control and 
normalisation of blood sugar [30]. 
1.7.5. Hyperhomocysteinaemia 
Despite increased plasma homocysteine levels being strongly associated with 
PAD [77], there are currently no randomised trials available to support the role of 
homocysteine lowering therapy in PAD [194] . Therapy with folic acid, vitamin 
B12, and vitamin B6 is effective in lowering homocysteine levels, but the effects 
on vascular disease severity and progression need further evaluation. 
1.7.6. Antiplatelet therapy 
Systematic reviews have demonstrated that patients with symptomatic PAD and 
those who have previously undergone intervention benefit from antiplatelet 
therapy for the reduction of MI and stroke [195,196]. Aspirin is the 'first line' 
antiplatelet agent used in the UK as it is both cheap and effective, and evidence 
has demonstrated that aspirin reduces the rate of adverse vascular events by 
around 20% [197]. Over recent years there has been a trend towards 
prescribing lower doses of aspirin (75mg daily) in an attempt to reduce bleeding 
complications; however evidence supporting this move is yet to be clearly 
established. 
The Peripheral Arterial Diseases Antiplatelet Consensus Group has recently 
recommended that all patients with IC should be considered for long-term 
antiplatelet therapy as evidenced by their ability to reduce future vascular events 
[197]. Although evidence supporting the use of aspirin in cardiac and 
cerebrovascular disease is good, there is a relative scarcity of data in PAD. 
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Much of the data used in meta-analyses to support the use of aspirin in PAD 
actually comes from other antiplatelet agents such as clopidogrel and ticlopidine 
[198]. In addition there is data suggesting that clopidogrel is a more effective 
agent than aspirin in patients with PAD [50]. Clopidogrel is a theinopyridine that 
blocks platelet ADP receptors, a more potent pathway of platelet activation than 
that of thromboxane (aspirin). 
There is now growing interest in the use of combination antiplatelet agents to 
block multiple pathways of platelet activation, and interest in the identification of 
patients relatively resistant to aspirin therapy [128]. The CURE study has found 
the combination of aspirin plus clopidogrel to be more effective than aspirin alone 
in patients with acute coronary syndromes, and the European Stroke prevention 
study 2 demonstrated that the combination of aspirin plus dipyridamole was more 
effective in preventing strokes than either agent taken singly [199]. Although 
these results are promising, these data cannot be directly extrapolated to PAD, 
particularly when concerns over bleeding complications exist. 
Current evidence and financial constraints would support the use of aspirin in all 
patients with PAD who are able to tolerate the drug. In patients intolerant of 
aspirin, clopidogrel is the drug of choice. Patients considered being at high risk 
of vascular events, and those who continue to have events whilst on aspirin 
should be considered for clopidogrel therapy, alone or in combination with 
aspirin. 
1.7.7. Hypercoaguable states 
Screening and treatment for thrombophilia in PAD is controversial. Patients with 
early onset PAD or those with a recent history or family history of thrombotic 
disorders should be screened for thrombophilia. Hypercoaguable states, when 
detected, should be discussed with a haernatologist and in the majority of 
patients oral anticoagulation is the only available treatment. Use of oral 
contraceptives has been associated with increased risk of thrombosis in 
peripheral arteries. The RATIO study recently showed an adjusted odds ratio of 
3.8 (95% Cl 2.4-5.8) for PAD in women using any type of oral contraceptives vs. 
no use [200]. 
In patients primarily considered for surgical treatment, antiplatelet and 
anticoagulant drug therapy can be used as a means of promoting graft patency, 
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andý beta-adrenergic blockers can be used as a means of reducing the 
perioperative risks associated with vascular surgery. 
1.8 Pharmacotherapy of intermiftent claudication 
Patients with IC mostly receive drug treatment for risk factor modification, co- 
existing disease or as prophylaxis against thrombotic events associated with 
atherosclerosis. Pharmacotherapy has in general failed to produce sufficient 
reduction or elimination of symptoms in claudicants to gain widespread 
acceptance. However, pharmacotherapy is perhaps still helpful in the following 
scenarios: 
i) in patients who have not sufficiently benefited from exercise and risk 
factor treatment, 
ii) in patients who cannot or will not follow exercise therapy, 
iii) as adjunct treatment where invasive therapy is not indicated, 
Various clinical trials with drugs like pentoxifylline, buflomedil, naftidrofuryl and 
cilostazol have shown statistically significant improvement in walking distance but 
the average benefit is small [201-211 ]. Vasodilators have limited, if any, role to 
play. Cilostazol therapy may increase maximal and pain-free walking distances in 
IC [201]. Greater benefit may warrant a short course of therapy with continued 
use of such agents if sufficient improvement is observed. Currently there is 
insufficient data to recommend the routine use of pharmacotherapy in all patients 
with claudication. 
9 Prostaglandins 
PGE1 and a prodrug of PGE1 (AS-013) have shown a significant increase in 
maximum walking distance as compared with placebo with an improvement in 
QoL [212,213]. These improvements have remained virtually unchanged over 3 
months' follow-up without treatment. Intravenous administration of these 
medicines is often not practical and side effects can limit therapy. A recently 
developed oral preparation, beraprost, a PG12 analog may be more promising in 
this regard [214,215]. Utility of this class of drug in claudication is presently 
being evaluated. 
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9 Vascular endothelial growth factor 
Vascular endothelial growth factor (VGEF) therapy is a new and exciting area. 
However a great deal of work and evaluation is required before it could be 
considered for routine treatment [216]. VEGF and basic fibroblast growth factor 
(bFGF) are mitogenic agents for the development of new collateral channels in 
models of peripheral ischaernia. VEGF has shown promise by augmenting 
collateral vessel development and increase capillary density in skeletal muscle 
animal models, via intra-arterial infusion and intramuscular injection [217]. 
A number of other pharmacological agents have been investigated for medical 
treatment of IC but show little consistent scientific evidence of efficacy. 
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1.9 Conclusion of introductory review 
PAD is a considerable public health problem. It shares the similar risk factors as 
CAD and CVD. These risk factors can be modified to reduce the disease burden 
and its complications. There is a need to develop uniform guidelines to 
accomplish a desirable objective in PAD as has been done in CAD and CVD. 
This requires documentation of current practice patterns and outcomes in relation 
to risk factor profile in PAD. 
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Chapter 2 
Protocol Overview 
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2.2. Objectives 
The United Kingdom has a high burden of PAD. Unfortunately existing guidelines 
on management have largely focused on coronary and cerebrovascular disease. 
There is currently no uniform management protocol to treat these patients, not 
only in relation to the symptomatic disease process but also the underlying risk 
factors in a more effective and efficient way. As a result of this lack of agreement, 
many patients are currently denied risk-lowering therapy. 
This study aimed to collect basic data on the current management of risk factors 
in claudicants at the primary care and also at the hospital level. This is expected 
to help in future health planning and improving the pattern of vascular practice. 
The objectives of this study were: 
1. To document the following in patients with PAD 
(a) Patient characteristics and distribution, 
(b) Practice patterns 
(c) 6 month outcomes 
(d) To understand the impact of PAD on patient-centred outcomes 
including disease-specific and generic measures of QoL and health 
status. 
2. To determine markers of high and low risk affecting PAD. 
3. To suggest approaches to optimise the management of the high-risk 
group and determine the use of risk factors therapy such as antiplatelet 
and lipid lowering agents. 
4. To set a benchmark by which future practice may be improved. 
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2.2. Methods: 
2.2.1. Study design 
This study was a prospective, protocol-d riven, multi-centre observational cohort 
study. 
2.2.2.1. Identification of centres and enrolment of patients 
Members of the Vascular Surgical Society of Great Britain and Ireland were 
contacted using a random sequence method and invited to take part. Efforts 
were made to ensure that there is appropriate representation from different 
regions of the United Kingdom and teaching and non-teaching hospitals were 
included. Initially, one tertiary centre and three district centres from each of the 
health regions were invited to participate. Due to recruitment difficulties in total 
54 centres were invited. 31 of these refused over a period of time due to various 
reasons. Hence 23 centres were used (Appendix 1: list of centres). A total of 474 
patients were enrolled. Enrolment started in June 2002 and was completed in 
September, 2003. Follow up was completed in March 2004. 
2.2.2.2. Eligibility 
Potentially eligible patients were identified through vascular clinics of the 
participating hospitals as per the inclusion criteria. Patients enrolled on the study 
fulfilled the following eligibility criteria: 
2.2.2.2.1. Inclusion criteria: 
1. Good clinical history of intermittent claudication occurring within a walking 
distance of about 400 metres or quarter of a mile (i. e. Patients in Fontaine 
class 11). 
2. Ankle/brac ia oo pressure index: 5 0.9. 
3. Presenting as a new referral to a vascular clinic of a participating hospital. 
4. Patients with past history of vascular disease presenting as new referrals with 
an interval of two years at least. 
5. Able to provide written informed consent. 
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2.2.2.2.2. Exclusion criteria: 
1. Patients presenting with critical limb ischaernia including rest pain, necrosis or 
ulceration. 
2. Spinal canal claudication. 
3. Claudication that may be related to venous obstruction. 
4. Patients presenting with another major medical condition where the 
claudication is incidental. 
5. Participation in any other clinical trial. 
Z2.2.3. Data collection and management: 
Study-related information was collected on case report forms (CRFs). (Appendix 
2: Case Record Form). All the data at entry was checked and any missing or 
unusually abnormal values were sent for edit query to the relevant centre. The 
data was cleaned and rechecked. 
2.2.2.4. Follow-up: 
Patients were followed up 6 months after enrolment to document the occurrence 
of major clinical events such as hospital admission, surgical or radiological 
intervention, and other vascular events like myocardial infarction, 
cerebrovascular accident, transient ischaernic attack or death. Six-month follow 
up was decided to observe the extent of outcomes within a short period of time in 
this high risk population. Hospital visit were encouraged, although telephone 
follow-up was used in patients who could not attend the outpatients. A small 
number of patients were seen earlier or later than planned, but median time for 
follow up remained 6 months. 
2.2.2.5. Statistical issues 
A sample size of 500 was initially proposed for this study. This was based 
primarily on the estimation that 10% of the population would develop a major 
event during the 6 month follow-up with a power calculation of 80% and 
secondarily on the feasibility of recruitment. 
The following analysis plan was defined in advance of the study: 
1) Descriptive Statistics 
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The characteristics and treatments recorded in the case report form including the 
baseline medical history, peripheral vascular disease history, employment and 
education, smoking status, results of the blood tests and medications will be 
tabulated. The following parameters will be assessed in the stratified analysis: 
L) Age 
ii. ) Gender 
iii. ) Ankle brachial index 
iv. ) Percentage taking an antiplatelet treatment 
V. ) The pack years smoked by the patient. 
2) Exploratory analysis of interactions between various baseline 
characteristics and treatments 
The following prognostically important variables will be considered. This list 
was not exclusive but contained the main factors to be used in exploratory 
analysis: 
i) Age 
ii) Gender 
iii) Ankle brachial index 
iv) Systolic blood pressure 
V) Diabetes 
vi) Hypertension 
vii) Any prior coronary heart disease defined as the presence of a prior MI, 
prior CABG or prior PTCA or prior angina 
viii) The absolute claudication distance 
ix) The pack years smoked 
X) Whether or not taking antiplatelet therapy 
xi) Whether or not taking lipid-lowering therapy 
This analysis would explore the relationship between age as an independent 
variable and the other variables. The second analysis would be based on gender 
as an independent variable and the others as dependant variables to determine 
the relationships. The third major factor would be ankle brachial index. A 
univariate analysis was proposed in the first instance and then a multivariate 
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model would be used to explore the inter-relationships between the various 
factors. 
2.2.2.6. QoL 
Patient centred outcomes were assessed at each visit. Effects of PAD on 
patients' QoL were assessed by a generic questionnaire, EuroQol -5 (appendix 
3) and a disease specific questionnaire Periphral Artery Questionnaire (PAQ) 
(appendix 4) [214,215]. EuroQol - 5, developed by York University is widely 
used as a generic QoL tool and it was found to be an appropriate tool to be used 
in this setting. PAQ is a recently developed arterial disease specific tool that has 
been validated in the USA. Data from this study is also being used to estimate 
the cost burden of PAD in the UK and the possible impact of treatment 
modifications. This is being analysed in collaboration with health economist team 
from Massachusetts in the USA. This specific QoL tool i. e. PAQ, was found to be 
useful to document the impact of any intervention or progression of the disease 
and also sensitive to quantify the benefit in terms of management costs. 
2.2.2.7. Ethical and Regulatory issues 
The study protocol and any other relevant documents were submitted for 
approval to the Multi-Centre Research Ethics Committee (MREC) before being 
submitted to the Local Ethical Review Committee (LREC) in the participating 
institution. Patients were required to give written informed consent before their 
participation. No particular ethical concerns were raised, as this was an 
observational study. 
2.3. Participating Centres 
One tertiary centre and three district centres from each of the health regions 
were initially invited to participate. Tertiary centres were mainly based in the 
teaching centres. Initially 23 centres were invited to take part but due to local 
issues and difficulties many centres dropped out. Hence further centres were 
invited. A total of 54 centres were invited. 31 centres declined participation due to 
varying reasons. Most of these were peripheral hospitals where resources in 
terms of conducting a prospective study were not in place or the departments 
were too constrained due to service obligations. 
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2.3.1. Centre Recruitment Process: 
Once identified the participating centre was invited. On expression of further 
interest the study protocol was forwarded to the centre. All the centres were 
provided with a copy of the Multicentre Research Ethics Committee (MREC) 
approval. The centres were required to get: 
- Local Research Ethics Committee (LREC) approval 
- Local Trust approval 
A study coordinator (research nurse / doctor) was identified in each centre. 
Training Calls were conducted and once fully satisfied case record forms (CRF) 
were sent. All these activities were monitored and managed at the Clinical Trials 
and Evaluation Unit of the Royal Brompton Hospital, London in close association 
with the Northern Vascular Unit at Freeman Hospital, Newcastle upon Tyne. 
At the time of recruitment patients were provided with an information leaflet 
(appendix 5). Any queries were answered and a written consent (appendix 6) 
was taken. The CRF was filled as per history given by the patient. Once enrolled 
the patient's details were sent to the study coordinating office. There the data 
was checked and cleaned. Any queries were edited and sent back to the centre 
for further clarification. Timelines of the study are displayed in table 2.1. 
2.3. Z Proffle of centres 
In total 23 centers participated. Of these 13 were teaching hospitals while 10 
were district hospitals. 
2.3.2.1. Bed size: 
The average number of beds in the recruitment centres was 1085 (teaching 
1335, district 772) and average numbers of vascular beds in these centres were 
27 (teaching 25, district 18). 
2.3.2.2. Number of vascular surgeons: 
The average number of vascular surgeons for the recruiting centres was 3.5 
(teaching 4, district 3). Most teaching hospital surgeons were dedicated vascular 
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surgeons while most of the district hospital surgeons were general surgeons with 
an interest in vascular surgery. 
2.3.2.3. Vascular workload: 
The average number of patients seen per year in the outpatients of the recruiting 
centres was 1740 (teaching 2150, district 1400) and the average number of 
vascular emergencies was 191 (teaching 214, district 152). 
2.3.2.4. Procedures: 
The number of angioplasties and peripheral bypass procedures performed at the 
participating centres on average were 148 (teaching 165, district 127) and 62 
(teaching 65, district 61) respectively. 
2.3.2.5. Facilities: 
All major diagnostic and therapeutic facilities were available at most centres 
which included treadmill, duplex scanning, diagnostic and interventional 
radiology, computed tomography (CT scan) and magnetic resonance imaging 
(MRI). Two of the centres were running nurse led claudication clinics. One district 
hospital had no vascular laboratory while MRI was not available in another. 
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MREC approved March 2002 
1st patient enrolled June 2002 
All centres recruiting April 2003 
Recruitment completion September 2003 
6 month follow-up completion March 2004 
Table 2.1. - Timelines o/ lhe slittli, 
Centres invited Centres 
confirmed 
Eastern 6 2 
London 6 3 
Northwest 5 0 
Northern and 5 4 
Yorkshire 
South East 9 1 
South West 5 5 
Trent 2 1 
West Midlands 6 3 
Scotland 6 1 
Wales 2 2 
Northern Ireland 2 1 
Tota 1 54 23 
Table 2.2. - MsIribulion (? / ceno-cs 
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Chapter 3 
Baseline Characteristics 
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3.1. Baseline characteristics 
As described in section 2.2.2.2.1. consecutive patients with a history of IC were 
recruited following consent to participate in the study. Study protocols were 
followed as per the inclusion and exclusion criteria. Patients with previous 
vascular history were included if they presented as new referral at least two 
years after the previous attendance to a vascular unit. A total of 474 patients 
were recruited. The baseline data relating to these patients is presented in this 
chapter. 
3.2. Results 
3.2.1. Age (Table 3.1) 
The median age at enrolment was 68.37 years (interquartile range (IQR) 60.75 - 
75.51). Age variable was divided into three groups i. e. less than 60,60 - 70, 
more than 70 years of age, for further analyses. Median age of the female 
population was 71.93 years (IQR 63.03 - 77.44); for males it was 66.48 years 
(IQR 60.27 - 73.41) (p <0.001, chi-square test). 
3.2.2. Sex (Table 3.1) 
The total number of males was 315 (66.5%) and females 159 (33.5%). The male 
to female ratio was 1.98 : 1. The preponderance of female claudicants as 
compared to males progressively increased from 1: 2.5 in the less than 60 age 
group to 1: 1.4 in the 70 plus age group. This was statistically significant (p 0.005, 
chi-square test). 
3.2.3. Body Mass Index (BMI) (Table 3.2) 
BMI is defined as weight in kg / height in meter2. Normal BMI ranges between 20 
and 25. Median body index in this population was 26.02 (lQR 23.45 - 29-64). 
Using standard charts 60% (282 / 470) of the patients were found to be 
overweight i. e. BMI of more than 25, and of these 5% (24 / 470) were grossly 
overweight, i. e. BMI > 35. 
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Age Group Female Male 
n (% female) n (% male) 
n= 159 n= 315 
< 60 30(18.9%) 76(24.1%) 
60-70 40(25.2%) 112(35.6%) 
> 70 89(55.9%) 127(40.3%) 
Table 3.1. - Age andsex disiribulion. 
BMI Percentage 
15-20 5% 
20-25 35% 
25-30 38% 
30-35 17% 
35+ 05% 
Table 3.2. - Pallern qfbody mass index (bmi) dis1ribution 
Median Range (meters) 
Initial CD 100.0 0-400 
Absolute CD 150.0 10-1500 
Lible 3.3. Illilial alld absolute claudication distance charactcrisiics 
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3.2.4. Ethnic origin 
Most of the patients were Caucasians (97%), 3 were Afro-caribbeans, 8 (1.7%) 
South Asians and 1 East Asian. 
3.2.5. Claudication: (Table 3.3) 
All patients as per inclusion criteria were claudicants with initial claudication 
distance of less than 400 yards. 254 (53.6%) had bilateral claudication while 220 
(46.4%) were symptomatic in one leg only. The distribution of initial and absolute 
claudication distances is shown in figure 3.1. 
The median initial claudication distance in both unilateral and bilateral 
claudicants was 100 meters however the lQR was 50 - 200 for unilateral and 
42.5 - 150 for the bilateral claudicants. The median absolute claudication 
distances were 176.0 (IQR 90 - 300) and 150 (IQR 70 - 205), respectively. 
These figures were statistically significant (p 0.01 and p 0.005, Kruskal - Wallis 
test). 
3.2.6. Ankle Brachial Pressure Index (ABPI): (Table 3.4) 
ABPI is the ratio of best ankle systolic pressure to systolic pressure in the 
brachial artery. The median ABPI on the left lower limb was 0.70 (IQR 0.57 - 
0.85) and 0.75 (IQR 0.60 - 0.90) for the right lower limb. Lower of the two ABPI 
values was further grouped into four groups as shown in table 3.4. 
The median ABPI in patients with bilateral claudication was 0.68 on left and 
0.070 on the right while this was 0.75 and 0.80 respectively on the right (p <0.001 
and <0.001, Kruskal - Wallis test). 
3.2.7. Blood Pressure: 
The median systolic blood pressure was 152 with a range of 75 - 234 mmHg. 
Even though only a single observation, systolic blood pressure of more than 140 
mmHg was observed in 68.9% of the population. The median diastolic blood 
pressure was 80 with a range of 50 - 130.19% had a single reading of more 
than 90 mmHg. The distribution patterns for the systolic and diastolic blood 
pressure are shown in tables 3.5 and 3.6. 
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Figure 3.1. - Initial and A bsolitle claudication. - pallern of'distribution 
0- 50 melen-, 2=5 00 twelers, 301- 200 weler. ý, 4= 20 1- 300 lilclerl-, 5= 30 
400 maea, 6=> 401 meleri) 
GROUP Distribution 
N 
I (ABPI 0.70 - 0.90) 34.8 
11 (ABPI 0.50 - 0.69) 46.7 
III (ABPI 0.3 - 0.49) 16.3 
IV (ABPI < 0-3) 02.2 
Table 3.4. - A nkle Brachial Pressure h7dex (A BPI) diSiribiaim, pillel. n. 
50 
3456 
Claudication group 
Systolic Blood Pressure Percentage 
(mmHg) 
<140 30.8 
140-160 33.1 
160-180 24.2 
180-200 8.5 
200+ 3.4 
Table 3.5. - Distribulion patiern of'systolic blood pressure 
Diastolic Blood Pressure Percentage 
(mmHg) 
90 83.2 
90-100 11.3 
100 5.5 
Table 3.0. - Distribulion paltern of'diusiolic blood pressure 
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3.2.8. Treatment for Hypertension: 
A total number of 258 (54.4%) were receiving treatment for hypertension. 12 
(6%) patients with a diastolic BP of more than 90 mmHg were not receiving any 
medication at all and 25 (12.6%) who were receiving treatment were either not 
well controlled on their medication or were non-compliant. 
3.2.9. Treatment for Hyperlipidaemia: (Table 3.7) 
214 (45.3%) were on lipid lowering therapy at the time of enrolment. 44% (208) 
were on statins and 1.3% (6) were on non-statin lipid lowering therapy. 
73% (346) of the recruited population had their cholesterol checked. 193 
patients had a cholesterol level more than 5.0 mmol/L. 145 of these patients with 
a cholesterol level of more than 5.0 mmol/L were not taking any lipid lowering 
medication. Cholesterol level was in excess of 5.0 mmol/L in 65 (43%) of the 151 
patients who were on lipid lowering therapy. 
There was a statistically significant difference in cholesterol levels of patients on 
statins as compared to those without (p <0.001, Kruskal - Wallis test). 
3.2.10. Previous Cardiovascular History., (Figure 3.2) 
152 (32%) of the total 474 patients had a history of symptomatic cardiovascular 
disease other than hypertension. Of these 85 (18%) had angina, 68 (14.4%) MI, 
34 (7.2%) CVA, 42 (8.8%) coronary artery bypass grafting (CABG) and 17 (3.6%) 
with prior percutaneous transluminal coronary angioplasty (PTCA). 
Patients with prior coronary heart disease (CHD) history (defined as prior MI, 
angina, CABG or PTCA) were assessed in more detail. 139 (29.3%) patients had 
prior CHID history. These patients 
were older (p 0.014, chi-square test), 
had higher diastolic blood pressure (p 0.044) 
were more likely to have hypertension (p<0.001), and 
were more likely to be smokers (p 0.001). 
were more likely to be on antiplatelets, ACE inhibitors and beta-blockers 
<0.001) (Table 3.8). 
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Statin use 
Other lipid lowering therapy 
Median total cholesterol (mmol/l)- pts on statin 
Mean (sd) total cholesterol (mmol/l)- pts not on statin 
Table 3.7. - Lipid lowering 1herapy and cholesterol levels. 
208 / 474 (44%) 
06/474(1%) 
4.9 mmol/L 
5.7 mmol/L 
60 
50 
40 
30 
20 
10 
Angina Prior MI Prior CVA Hypertension 
Figure 3.2. - Cardiovascular hislor-v 
Prior CABG Prior PTCA 
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* were more likely to be on lipid lowering therapy (p < 0.001) 
These patients had a lower median cholesterol level as compared to those 
without a history of CHID (5.1 mmol/L vs. 5.6mmol/L, p 0.013, Kruskal - Wallis 
test) No association of prior CHD was found with the claudication distances and 
ABPI. 
3.2.11. Diabetes: 
94 (19.9%) of the patients were diabetics with 23 (4.9%) being insulin dependent 
and 71 (15.0%) non-insulin diabetics. Of the non-insulin dependent diabetics, 12 
were diet controlled. 
3.2.12. Prior Vascular History., (Table 3.9) 
34 / 474 (7.2%) of the patients had a prior peripheral vascular disease history. 
All these were new referrals with no vascular consultation over the past two 
years. 
3.2.13. Employment Status: 
Of the 179 / 474 (37.7%) of the eligible patients for employment i. e. less than 65 
years of age, 81 were actively employed at the time of recruitment. 12 persons 
above the recommended retirement age were still working. In total 93 / 474 
(19.6%) were still working for a living. 
3.2.14 Education Status: 
77/ 474 (16.3%) of the population continued their education beyond the minimum 
school leaving age and only 47/474 (9.9%) went on to attain a higher degree or a 
professional qualification. 
3.2.15. Smoking: 
413 / 474 (87.1%) had history of smoking. 42.1% were smoking at recruitment, 
45.2% were ex-smokers and'12.7% had never smoked. Median pack years 
(number of packs multiplied by the number of years smoked. One pack = 20 
cigarettes) smoked were 40 (lQR 25 - 56). The total amount of 
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Antiplatelet [n(%)] 
Lipid lowering [n(%)] 
ACE inhibitor [n(%)] 
Beta blocker [n(%)] 
Angiotensin 11 antagonist 
[n(%)] 
Prior CHD No prior CHD p 
(n=l 39) (n=334) (X) 
121 (87%) 210(63%) <0.001 
96(69%) 115(35%) <0.001 
53(39%) 69(21%) <0.001 
49(36%) 35(10%) <0.001 
8(6%) 24(7%) 0.60 
Table 3. N. - Us-e qI'medicalion wi/h prior CIID history. 
Aortic aneurysm 12(2.5%) 
Internal carotid stenosis (>50%) 13(2.8%) 
Previous peripheral vascular graft 9(1.9%) 
Table 3.9. - Prior vascular hisloty. 
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tobacco smoked by non-cigarette smokers was 15.7 (median) grams per week. 
Patients who smoked cigars or rolled up their own cigarettes were approximated 
to an equivalent value of pack years. 
113 of the smokers had attempted to stop smoking in the last six months and out 
of these only 2 were successful. A number of different methods were used as 
shown in table 3.11. Besides the main methods hypnosis, chewing gum and 
eating cold turkey were also used. 
3.2.16. Antiplatelet Medication: (Figure 3.4) 
331 (70%) of the patients were on antiplatelets. Of these 66.2% were on Aspirin, 
3.6% on Clopidogrel, 2.3% on Dipyridamole and none on Ticlopidine. Eight 
(2.6%) persons were on both Aspirin and Dipyridamole. Six of these patients 
had a history of CVA. No person was on Dipyridamole alone. The most common 
dose of Aspirin was 75mg (90.1%) while 5.4% were on a dose of 150mg and 
4.5% on 300mg once daily. 
The common reasons for not taking antiplatelets are shown in table 3.12. 
Others included asthma, taking warfarin, bruising, colitis, history of gastritis and 
subarachnoid haemorrhage. 
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Non smokers 
13% 
Current smokers 
42% 
Ex-smok 
45% 
Figure 3.3. - Smoking slatus qf1he population. 
Pack-Years Smoked Percentage 
(Pack x No. of years) 
1 -20 19.5 
21-40 34.6 
41 -60 29.8 
61 -80 8.2 
80+ 7.9 
Tahle 3.10. - Pack vears smoked 
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Method Used 
Nicotine replacement therapy 
Bupropion 
Counselling 
Self motivation /Will power 
Other 
Table 3.11. - MeMods usedfi)r smoking cessation. 
Ticlopidine 
0% 
Dipyridamole 
2% 
Clopidogrel 
4% 
n(%) 
47(41.6) 
5(4.4) 
10(8.8) 
51(45.1) 
8(7.0) 
; pirin 
36% 
Figure: 3.4. - Di. viribution pallern ol'antiplatelel inedicalion. 
History of ulcers 14(3.0%) 
Indigestion 9(1.9%) 
Allergy 1 (0.2%) 
Never prescribed 93(19.6%) 
Non-compliance 4(0.8%) 
Other 21 (4.4%) 
Tahle 3.12. - Reasonsfin- 1701 taking anliplalelels. 
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Age Female Male p-value 
<60 18/30(60%) 
60-70 23/39(60%) 
>70 65/89(73%) 
Total 106 / 158 (67.1%) 
44 / 76 (57.9%) 
85/112(75%) 
97 127 (76.4%) 
225 315 (71.4%) 
</= 1 
0.20 
Table 3.13. - Antiplafelef use by age andsex. 
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3.2.17. Laboratory Investigations: 
3.2.17.1. Total Cholesterol: (Figure 3.5, Table 3.14) 
346 / 474 (73.1%) patients had their cholesterol checked with a median of 
5.4mmol/L (lQR 4.5 - 6.2). Median cholesterol in patients on lipid lowering 
medication was 4.9mmol/L and that without such medication was 5.7mmol/L. 
3.2.17.2. High Density Upoprotein (HDL): 
HDL was checked in 180 / 474 patients (38%) with a median 1.3mmol/L (IQR 
1.11-1.6). 
3. Z17.3. Low Density Lipoproteins (LDL): 
68 / 474 (23.7%) patients had their LDL levels checked. Median LDL was 3.2 
(IQR 2.3 - 3.87). 
3.2.17.4. Total cholesterol HDL Ratio: 
This was calculated in 180 474 (38%) of the patients. Median ratio was 3.87 
(IQR 3.1 - 4.8). This was 3.5 for patients on lipid lowering therapy as compared 
to 4.1 who were without such medication. 
3. Z17-5- Other blood tests: 
Other baseline laboratory investigations are shown in table 3.15. 
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Cholesterol (mmol / L) 
Mean 5.437 
StDev 1.238 
N 346 
Figure 3.5. - Total choleslerol distribution. 
Cholesterol Level Percentage 
(mmol/L) N 
< 3.5 4.6 
3.5-5.0 35.0 
5.0-6.5 43.9 
> 6.5 16.5 
TabIc 3.14.1)[siribittion pallern qffolal choleslerol. 
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Variable Percent Median lQR 
checked 
Total Cholesterol 73.1 5.4 4.5-6.2 
(mmol/L) 
HDL 38.0 1.3 1.1-1.6 
(mmol/L) 
LDL 23.7 3.2 2.3-3.9 
(mmol/L) 
Glucose 55.2 5.3 4.8-6.1 
(mmol/L) 
Creatinine 67.1 96.0 83.0-109.0 
(mmol/L) 
Haernoglobin 63.1 14.4 13.4-15.3 
(mg/dl) 
mCv 60.3 91.1 88.2-94.8 
Platelets 63.1 254 209- 304 
White Cell Count 62.6 8.1 7.1 -9.4 
(x 109/L) 
CRP 14.3 3.6 2.9-6.7 
Table 3.15. - Baseline laboratory in vesl igat ions 
3.2.18. Drug History: 
A medication history of several cardiovascular drugs was taken and is 
summarised in table 3.16. 
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Drug Number 
Statins 208 
Non-statins 06 
Warfarin 17 
ACE Inhibitors 122 
B-blocker 84 
Ca-antagonist 107 
Angiotensin 11 32 
antagonist 
N itrate 54 
Vasodilator 39 
Quinine 25 
Diuretic 136 
Oral hypoglycaernics 57 
Insulin 25 
Hormone Replacement 12 
Therapy (HRT) 
Table 3.10. - 1fedicalion used by the recruited patients, 
Percentage 
44.0 
1.3 
3.6 
25.8 
17.8 
22.6 
6.8 
11.4 
8.2 
5.3 
28.8 
12.0 
5.3 
2.5 
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3.3. Discussion: 
Despite a high prevalence of PAD in the community, awareness of the condition 
and appropriate risk factor management in the primary care is not optimal [29, 
151]. Some risk factors are associated more than others either with the incidence 
or the progression of PAD. In the present study we have accumulated risk factor 
data on claudicants at their initial visit to a vascular clinic in UK and have 
primarily documented the patient characteristics and prevalence of 
atherosclerotic risk factors in this population. This visit also audited the risk factor 
management at primary care level. Patient centred outcomes were also 
evaluated which are discussed in more detail in chapter 7. 
Increasing age has been shown to be a risk factor for the development of PAD 
[19,25,27]. In the Framingham study each 10-year increment in age carried a 
2.6-fold increase of developing PAD [39]. PAD has a predilection for the male 
population [60,109,112]. In this series more than 65% of the claudicants were 
above 65 years of age and 65% were men. 
The usefulness of ABPI as a marker of generalised atherosclerosis is well 
documented [111,137]. The Cardiovascular Health Study and the Framingham 
study have reported a graded inverse relationship of decreasing ankle-brachial 
index to cardiovascular disease end points and risk factor levels [39,111 ]. In our 
study ABPI was found to have a significant association with angina, BMI, initial 
and absolute claudication distances and total cholesterol. An ABPI value of 0.78 
has been linked with an approximate 30% 5-year risk of MI, ischemic stroke, and 
vascular death [29,220]. Mean ABPI in this study was 0.62 (+/- 0.16). 65% had 
an ABP1 of less than 0.70. 
Antiplatelet agents are less frequently prescribed in PAD patients as compared to 
patients with a history of CAD or CVD [113,221]. In this series 21% of the 
patients were not receiving any antiplatelet therapy. Patients with history of 
angina (p 0.001), MI (p < 0.001) or cardiac intervention (p 0.002) were more likely 
to be on antiplatelet therapy. Also patients on lipid lowering therapy (p 0.048) or 
antihypertensive therapy (p 0.047) or both (p 0.024), were more likely to be 
taking antiplatelet agents. 
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Smoking cessation has been shown not only to reduce disease progression but 
also the mortality risk in PAD [54,222]. Nicotine replacement treatment 
approximately doubles the cessation rate in unselected smokers [223,224]. 
Bupropion has a similar benefit when used with intensive support [152]. These 
are available on NHS and every patient with claudication should be offered one of 
the two as well as the appropriate counselling. Different delivery profiles available 
for the nicotine replacement may improve its compliance and effectiveness. 
Smoking cessation classes are helpful and recommended but therapies like 
acupuncture, hypnotherapy and 'aversive smoking' are of little benefit [225-227]. 
Unfortunately, rates of cessation are not encouraging and remain as low as 13% 
at two years [222]. 
87% of the patients had a history of smoking in this series; 42% current and 45% 
ex-smokers. Of the current smokers only 23.9% (n=1 13) had tried to stop within 
the three months of enrolment. 46 used nicotine, 5 bupropion and only 10 were 
counselled. There is an increasing need to counsel these patients at a younger 
age. The number of current smokers as compared to ex- or non-sMokers 
declined as the age progressed (p < 0.001). Males were more prone to smoking 
whether at present or in the past (p-values 0.011 and 0.12, respectively). 
Up to 20% of patients with intermittent claudication may have diabetes and 
approximately 50% of cases may be undiagnosed at the time of presentation 
[228]. It is a powerful risk factor for progression to critical limb ischaernia [229]. In 
this series, 18.3% were diabetics. Only 45.5% had their blood glucose checked 
and 42% of these were known diabetics. As evident from the results blood 
glucose was not very well controlled in the diabetics and 6.5% of the 'non- 
diabetic' patients had a glucose level above7.0 mmol/L and needed further 
evaluation. 
The United Kingdom prospective diabetes study has shown that intensive 
glycaemic control reduces the microvascular complications of type 2diabetes 
[188]. Surgical intervention in diabetics may not achieve the desirable response, 
therefore a greater benefit from strict glycaemic control may be expected in this 
group for cardiovascular disease as compared to non-diabetic population [230]. 
Risk factors profile and management in our series was not much different as 
65 
FI 
compared to non-diabetic claudicants i. e., antiplatelet therapy was 73.6% vs 
70.7%, lipid lowering therapy was 63% vs. 63% and the number of ex-smokers 
was 50 vs. 47%. 
The Heart Protection Study has shown that lowering total cholesterol and low 
density lipoprotein cholesterol by 25% with a statin reduces cardiovascular 
mortality and morbidity in patients with PAD by around a quarter, irrespective of 
age, sex, or baseline cholesterol concentration [68]. All patients should be on a 
statin. A protective effect of statins has been suggested that is independent of 
the total cholesterol and LDL levels which is likely to be mediated by influencing 
the inflammatory markers, i. e. C-reactive protein [177]. In our study, only 45% of 
the patients were on lipid lowering therapy. Patients with PAD only, were less 
intensively managed for hyperlipidaernia as compared to patients with prior 
history of MI or coronary intervention (p = 0.012 and 0.011, respectively). Lipid 
measurements were being done routinely only in 14 of the 23 centres. Patients 
on lipid lowering therapy had lower cholesterol and LDL levels as compared to 
those without such therapy (total cholesterol 5.0 vs. 5.8 mmol/L and LDL 2.7 vs 
3.5 mmol/L, p<0.001). 18% of the patients with a cholesterol level higher than 
5.0 mmol were on lipid lowering therapy while 75% of the patients with 
cholesterol level higher than 5 were not receiving any treatment. It is important to 
mention over here that statin doses were not recorded and it is possible that 
many of the patients did not recieve the currently recommended therapeutic 
doses (e. g. 40mg of simvastatin rather than 10 mg. ) and this may partly explain 
the inadequate control of lipid profile. In general practice most of the patients 
receive less than optimal dose of simvastatin; this may be inadequate and thus 
the ultimate benefit of such therapy is limited. However caution should be 
exercised in patients with hepatic dysfunction or myalgia. Liver function test and 
creatine kinase should be checked. 
The Edinburgh, Basle and Framingham studies have shown an increased PAD 
risk in hypertension by two to four fold and is particularly associated with the 
development of severe disease [39,45,48,61]. Control of hypertension was 
inadequate in our series. 54.7% of the patients had a history of hypertension and 
of these 73% of these had a reading higher than the British Hypertension Society 
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recommended high normal reading of 140/90 mmHg. Although these were single 
readings, decreasing the systolic pressure by 10mmHg (average declined 
described in hypertensive studies for the third reading as compared to first [231, 
232], still 62% would have their systolic BP more than 140 mm Hg. 
As expected the systolic pressure increased with age (p 0.02). Overall, 
approximately 77% of the patients receiving anti hypertensive therapy had poor 
control of high blood pressure and around a quarter of the patients with a blood 
pressure of more than 140/90 were not receiving any anti hypertensive 
medication. Patients above 70 were more likely to be on antihypertensive 
treatment (p 0.001) as compared to below 60. In general, patients with PAD only 
were not less frequently treated for high blood pressure than patients with 
documented CAD or CVD. This may be related to general suboptimal 
antihypertensive treatment of the entire group. These patients need further follow 
up and a better control of their blood pressure. 
Antiplatelet agents are known to reduce the risks of CAD, CVD and vascular 
death [50,233]. Antiplatelet therapy is therefore recommended for secondary 
disease prevention in patients with vascular diseases [234]. This study 
demonstrates the lower rate of administration of antiplatelet therapy in patients 
with PAD alone compared with those who had previous cardiovascular history 
and were on treatment for hypertension and hyperlipidaernia (p < 0.001). Around 
a quarter of the patients had never been prescribed any antiplatelet agent. 
The Heart Outcomes Prevention Evaluation (HOPE) study has shown that 
ramipril, an angiotensin converting enzyme inhibitor, reduces cardiovascular 
morbidity and mortality in patients with peripheral arterial disease by around 25%. 
The observed risk reduction of adverse outcomes in PAD could not be accounted 
for by the relatively modest reduction in blood pressure. It is therefore expected 
that most PAD patients would benefit from an angiotensin converting enzyme 
inhibitor, provided that treatment is not associated with a deterioration of renal 
function due to occult renal artery stenosis. Further, use of beta blockers has not 
been associated with progression or worsening of IC [186]. In this study 46.6% of 
the patients receiving anti hypertensive therapy were on ACE inhibitors and 
21.4% on beta blockers. 
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These data confirm that the PAD population in the UK carries a high 
atherosclerosis risk factor burden and ischaernic risk. This increased mortality 
risk can perhaps be limited by lifestyle alterations and drug therapy within the 
setting of general practice. Risk factor modification in patients with PAD in the UK 
appears currently inadequate. These findings suggest that there is a need for 
increased awareness of risk factor assessment and its aggressive management 
at a primary care level. 
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Chapter 4 
Age and peripheral arterial disease 
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4.1. Introduction 
Increasing age is associated with an increased incidence and prevalence of PAD 
[21,24,30,36,47,63,139]. PAD is not common below the age of 50. The 
weighted mean incidence of intermittent claudication as based on large 
population based studies increases from 2/1000/year at age 35-39 to >7 
/1 000/year at age above 65 [32]. The risk of developing PAD can be predicted by 
age [147,231]. The prevalence of PAD ranges from 3% in patients age >55, to 
11 % in patients age >65, to 20% in those age 75 and older [232]. This may be a 
result of prolonged exposure to causative risk factors. Majority of this prevalence 
is asymptornatic or if symptoms do occur in the elderly, this is taken as a part of 
being growing old; thus delaying the presentation to a clinician. Older patients 
with PAD are at high risk for coronary and cerebrovascular events and need to 
be closely monitored for the many presentations of systemic atherosclerosis. 
Early-onset PAD is typically associated with multiple cardiovascular risk factors. 
The majority of these are smokers, with a strong family history of cardiovascular 
disease, usually presenting with IC. Often like the elderly these symptoms are 
attributed to other more common causes of leg pain in the young. 
4.2. Methods: 
474 consecutive patients with IC were recruited as per the inclusion criteria of the 
study to 24 vascular units across the United Kingdom (see section 2.2.2.2.1. ). 
Age was documented at the initial visit. Use of risk factor therapy was recorded 
and analysed. Progression of disease patterns were noted over six months in the 
three different age groups. 
4.3. Results 
For analysis the population was stratified into three different age groups. 
The relationship of age to different variables is described below. 
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Age 
< 60 
60-70 
> 70 
Table 4.3. 
Table 4.1. 
Age Group 
< 60 
60-70 
> 70 
Age Group Frequency 
1 106 / 474 (22.3%) 
2 152 / 474 (32.1%) 
3 216 / 474 (45.6%) 
Distribution pattern ol'Populalion as per age 
Female 
30 / 106 (28.3%) 
40 / 152 (26.3%) 
89 / 215 (41.2%) 
Table 4.2. Sex distribulion as per age. 
Age Group 
< 60 
60-70 
> 70 
BAII in dilki-eni age groups. 
Male 
76 /106 (71.7%) 
112 / 152 (73.7%) 
127 / 215 (58.8%) 
Body Mass Index 
(median) 
25.67 
27.04 
25.66 
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4.3.1. Sex: (Table 4.2) 
The female to male distribution in different age groups is shown in table 4.2. The 
relative proportion of the female population increased as the age progressed to 
above 70 (p 0.005, chi square test). 
4AZ Body Mass Index (BMI): (Table 4.3) 
The median BMI in this population in different age groups is shown in table 4.3. 
Regression of this data showed a negative correlation between increasing age 
and BMI (age = 73.2 - 0.20 BMI). This is shown graphically in figure 4.1. 
There was no significant association among the three age groups in relation to 
BMI (p0.058, Kruskal Wallis test). 
4.3.3. Blood Pressure: (Table 4.4) (Figure 4.2) 
The median blood pressure was 155/80 mmHg at recruitment and 150/82 at six 
month follow up. As per different age groups the median blood pressure is shown 
in table 4.4. 
As expected the systolic blood pressure increased with age (systolic BP = 137.0 
+ 0.26 age) and this was found to be statistically significant for different age 
groups (p 0.019, chi-square test). 
However diastolic blood pressure did not show a similar trend and infact 
decreased in this population as age increased (diastolic BP = 91.4 - 0.14). 
In all 54.3% were receiving treatment for hypertension. In the elderly population 
more patients were likely to be on treatment for high blood pressure (p < 0.0001) 
as compared to below 60. 
Treatment for high blood pressure in relation to age is shown in table 4.5 and 
figure 4.3. 
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Figure 4.1. Correlalion ol'BMI with age. 
Age Group Median Blood Pressure Median Blood Pressure 
(mmHg) at initial visit (mmHg) at follow-up 
< 60 150/83 146.5/82.5 
60-70 156/80 150/81 
> 70 155/80 152/82 
Tuhle 4.4. Bloodpressure al initial visil and al. 101low-up as per age group. 
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Figure 4.2. Systolic pressure frend as pet- increasing age. 
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Figure 4.3. - Systolic blood pressure in relation to treatment or no frealment in clýllýrenl 
age grolps. 
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Age 
Groups 
< 60 
60-70 
> 70 
Systolic Blood Pressure 
< 140 140-160 160-180 180-200 > 200 
On Without On Without On Rx Without On Without On Rx Without 
Rx Rx Rx Rx Rx Rx Rx Rx 
36 64 33 67 50 50 33 67 -- 
43 57 48 52 59 41 73 27 57 43 
58 42 69 31 63 37 75 25 65 35 
values in percent 
Table 4.5. - Systolic pressure in diff ýrenl age groups as per trealment. 
70 
60 
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40 
CD 
a. 30 
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10 
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< 60 60-70 > 70 
Age Groups 
0 Anti-hypertensives 0 No anti -hypertensives 
Figure 4.4. A nli-hypei-lensive It-wimcni tis pei, cige gmups. 
Age Group Diabetes Mellitus (%) 
Non-Insulin dependent Insulin dependent 
< 60 9.4 5.7 
60-70 18.3 4.6 
> 70 15.3 4.7 
Table 4.0. Di. viribitlion poilern qI'diabelicy among dilki-cm cýqe groups. 
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4.3.4. Diabetes: (Table 4.6) 
The distribution of diabetes in relation to age in this population is shown in table 
4.6. Although there were more insulin dependent diabetics above 60 but no 
significant correlation of any of the age groups to history of insulin / non-insulin 
dependent diabetes was observed. 
4.3.5. Angina: (Table 4.7) 
Overall 22.5% patients suffered from angina. The younger patients had lower 
incidence of angina as compared to above 60, however, this was statistically not 
significant (p 0.08, chi-square test). 
4.3.6. Myocardial Infarction (1141): (Table 4.8) 
14.71% of the recruited population had history of MI with a median age of 68.5. 
As expected the incidence of MI with older age was higher though statistically not 
significant (p 0.08, chi-square test). By the end of six months five patients had 
suffered from MI; one was a 61 year old while others were above 70 years of 
age. 
4.3.7 Prior Coronary Intervention: 
8.8% had undergone CABG and 3.6% PTCA. There was no significant pattern of 
association in different age groups (p 0.24, chi-square test). 60 - 70 years old 
were more likely to undergo coronary intervention as compared to below 60 or 
above 70 years olds (3.3% vs. 0% and 1.3% at six months, respectively), 
however this was not statistically significant. 
4.3.8. Prior Cerebrovascular Accident (CVA): 
7.2% had history of CVA with a median age of 71, youngest being 55 year old 
and eldest 87. There was no significant difference (p 0.25, chi-square test). 1.5% 
of the 60 - 70 years old developed CVA over six months. 
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Age Group Prevalence of angina 
N 
< 60 12.3 
60-70 18.4 
> 70 20.5 
Table 4.7. Disiribution pattern qf angina in tlýf . 
4, rent age groups. 
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Figure 4.5. Pallern of'previous cardiovascular hislory in dil/erent age groups. 
Age Group 
< 60 
60-70 
> 70 
7'able 4.8. - Ilislory ol'MI in dil -enl age groups. 
Prevalence of MI 
N 
10.4 
13.2 
17.2 
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60 60-70 > 70 
4.3.9. Claudication distance: 
The distribution of initial and absolute claudication distances in different age 
groups is shown in table 4.9. No change was noted in relation to claudication 
distance in different age groups and improvement at six months was uniform for 
this population. 
4.3.10. Ankle Brachial Pressure Index (ABP1): 
The lower of the two ABPI values was taken. Its distribution in relation to age 
groups was as shown graphically in figure 4.5. ABPI decreased as the age group 
increased (ABPI = 0.78 - 0.0024 age) (p 0.008, Kruskal - Wallis test). This trend 
did not change at six months interval. 
4.3.11. Smoking Status: 
In total there were 42.1 % current smokers and 45.2% ex-smokers at recruitment. 
Age-wise the distribution is displayed in table 4.10. The proportion of current 
smokers to ex-smokers or non-smokers declined as the age progresses. Overall 
a significant difference was noted for a given age for the number of current 
smokers (p 0.00, chi-square test) and for ex-smokers (p 0.001, chi-square test) 
as compared to non-smokers. At six months a number of patients had given up 
smoking, however this trend was higher in patients below 60 (p 0.04, chi-square 
test). 
Pattern of cigarette smoking in different age groups can be determined from the 
number of pack years smoked by each individual. 
No specific pattern of distribution was observed between the pack years smoked 
and age (p 0.47, Kruskal -Wallis test). 
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Age Group Claudication Distance Claudication Distance 
(meters) (meters) 
(Median) at 0 month (Median) at 6 months 
Initial Absolute Initial Absolute 
< 60 100 150 150 200 
60-70 100 150 150 200 
> 70 100 150 150 200 
Table 4.9. - Initial and ubsolitle cluudicalion disfunces al 0 und 6 months. 
1.2 
1.0 
0.8 
0.6 
0.4 
0.2 
0.0 
Age Group 
0.65 
(). 54 
60 > 70 60-70 < 60 > 70 60- 70 
ABPI ABPI-1 
Figure 4.6. - A BPI as per age groups at recruitment and at six months. 
(ABI'l ankle bruchialpressure index at Olnonths, ABP11 -ankle brachialpressure at 6 months. 
Boxes represent the interquarlile range with inedian values displayed; whiskers represent range. ) 
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Figure 4.7. - A BPI frend with increasing age. 
Age Current Ex-Smokers Non-smokers* 
Group (%) M (%) 
0 mth 6 mth 0 mth 6 mth 0 mth 6 mth 
< 60 67.9 59.4 25.5 33.0 6.6 7.6 
60-70 46.7 44.4 48.0 48.9 5.3 6.7 
> 70 26.0 23.3 53.0 54.4 21.0 22.2 
7'tible4lo. Stiiokii7gl)tillei-noi, et-. vi. viiioi7ili. y. 
Non-sinoker s prevalence increased bec ause qfpatients lost to ev ent or. follow up. Onth - nionth) 
Age Group Pack-years Smoked 
< 60 43.7 
60-70 46.5 
> 70 39.8 
Table 4.11. - Pack years smoked as per age group. 
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4.3.12. Laboratoty Investigations: 
4.3.12.1. Cholesterol 
Total cholesterol was checked in 73% of the population recruited. Its 
distribution pattern is shown in figure 4.8. 
There was no significant association of cholesterol levels with age (p 0.46, 
Kruskal -Wallis test). 
4.3.12.2. Low Density Upoprotein (LDL) 
LDL levels were higher at the younger age (figure 4.9) but this was 
statistically not significant (p 0.052, Kruskal -Wallis test ). 
4.3.12.3. Total cholesteroll high density lipoprotein (TCIHDL) ratio 
TC/HDL ratio is known to be a more sensitive risk marker for development of 
atherosclerosis. Age-wise pattern of distribution is represented in the table 
4.12. 
Again no significant association was noted between TC/HDL ratio and age (p 
0.40, Kruskal - Wallis test). 
4.3.13. Lipid lowering therapy: 
Treatment for hyperlipidaernia was variable. 43.130% were receiving lipid 
lowering therapy. Percentage in each group taking lipid lowering therapy is 
shown in table 4.13. 
Younger patients were less likely to be on lipid lowering therapy as compared 
to age above 60 (p 0.004, chi-square test) at the initial visit. The trend 
significantly improved in all age groups by six months (p < 0.001, chi-square 
test). 
Further breakdown of the patients who were taking lipid lowering therapy at 
recruitment, as per their cholesterol levels was carried out as shown in table 
4.14. 
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1. -ý 
< 60 > 70 60-70 
Age Group 
Figure 4.8. - Choleslerol level as per dýlkrenl age groups. 
(Box represents interquarlile range with whiskers representing the range. Median values are 
displqyeý). ) 
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Figure 4.9. - LDL levels in reIalion lo age. 
82 
Age Groups 
< 60 
60-70 
> 70 
Mean TC/HDL ratio 
4.3 
4.0 
4.1 
Table 4.12. - Total cholesterol to I-IDL ratio in the 1hree age groups. 
Age Group 
< 60 
60-70 
> 70 
On lipid lowering 
therapy at initial visit 
N 
30.2 
50.7 
44.2 
On lipid lowering 
therapy at follow-up 
M) 
68.5 
72.1 
62.2 
Table 4.13. - Lipid lowering therapy as per age groups. 
< 3.5 3.5-5.0 5.1-6.5 > 6.5 
Age Group mmol/L mmol/L mmol/L mmol/L 
(%) (%) N N 
< 60 2.4 33.3 47.6 16.7 
60-70 3.7 39.1 42.7 14.5 
> 70 6.6 32.9 42.8 17.7 
Table 4.14: Disiribulion oflipid loivering lherapy as per choleslerol levels. 
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4.3.14. Antiplatelet therapy: (Tables 4.15,4.16) 
Patients above the age of 60 were more likely to be on antiplatelet therapy (p 
0.010, chi-square test) as compared to those below 60 at their initial visit. 
However at six months follow up patients across the population regardless of 
age group were taking antiplatelet agents (p 0.56, chi-square test). 
More patients were on Aspirin in all age groups as compared to other 
anitplatalet agents. 
Age Group Antiplatelet therapy at 
initial visit 
M) 
< 60 58.5 
60-70 
70 
71.0 
74.9 
Antiplatelet therapy 
at follow- up 
N 
91 
88.6 
86.6 
Table 4.15: Practice pallern ol'unliplalelef therapy in dýt krent age groups. 
Age Group Aspirin Clopidogrel Dipyridamole 
N N (%) 
< 60 56.6 1.9 1.9 
60-70 66.5 4.0 3.3 
> 70 70.7 4.2 1.9 
Table 4.10. - Inilial disiribution ol'various anliplafelels cis per ditki-ent age groups 
4.3.15. Drug History: (Table 4.17) 
Following drug pattern was noted in different age groups-. 
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Medicines 
ACE-inhibitors 
B- blockers 
Angiotensin 11 
antagonists 
Ca++ channel 
antagonists 
Nitrate 
Digoxin 
Diuretics 
Vasodilator 
Warfarin 
Oral 
hypoglycaemics 
Insulin 
Quinine 
< 60 
22 
17 
7 
13 
6 
1 
17 
4.7 
1 
9.4 
5.7 
1.9 
Age Groups 
60-70 
27 
16 
6 
24 
11 
1.3 
21 
7 
2.6 
11.8 
5.3 
3.3 
Table 4.17: Medicine pallern in atýl -ent age groups. , 
ki 
values in pet-cent. 
** 3 women ivere on hormone replacement therapy 
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> 70 
27 
20 
7.5 
26 
14 
5.6 
40 
11 
5.6 
13.5 
5.1 
8.4 
4.3.16. Peripheral Intervention: (Table 4.18) 
Younger patients were more likely to undergo peripheral intervention as 
compared to the elderly (p 0.027, chi-square test). The mode of peripheral 
revascularisation i. e. angioplasty +/- stenting or surgery was uniform in all three 
age groups. 
4.3.17. Events: (Table 4.19) 
Patients above the age of 60 were more likely to develop an event other than the 
revascularisation which included MI, PTCA, CABG, TIA, CVA, amputation or 
death (p 0.001, chi-square test). No such event was seen over six months in less 
than 60 years of age. 
Age Group Peripheral Intervention 
N 
< 60 12.26 
60-70 8.55 
70 4.17 
Table 4.18. - Peripheral re vasci darisal ion in relation to age groups. 
Age Group Event other than revascularisation 
N 
< 60 0.0 
60-70 6.58 
> 70 7.41 
Table 4.19. - Occurrence ofdýllerenl events other than peripheral revascularisai ion in 
dýlkrcnl uge groups oversix months. 
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4.4. Discussion: 
As described earlier, age is a known risk profile for development of PAD and 
associated complications. The frequency of intermittent claudication increases 
dramatically with advancing age, ranging from 0-6% in individuals aged 45-54 
years, to 2-5% in those aged 55-64 years, to 8.8% in patients aged 65-74 years 
[237]. The Rotterdam study, a population-based analysis of 7715 patients, 
documented a frequency of IC ranging from about 1% in those between the ages 
of 55-60 years to 4-6% in those between the ages of 80 and 85 years [38] 
Since age is a uniform factor documented in all the population based studies, it 
was important to find out the significance of different risk factors in relation to 
age. Therefore for further evaluation, the age variable was divided into different 
age groups. 
Male sex has always been at a higher risk of developing PAD as compared to 
females and at an earlier age. Incidence of symptomatic disease in women 
appears to catch up with that of the male population in the elderly [238]). In our 
study male to female ratio was 2.5: 1 for less than 60 years of age as compared 
to above 70 years of age where this ratio was 1.4: 1. 
Systolic blood pressure is known to increase with age mostly secondary to 
arteriosclerosis [239]. As expected in our series, the systolic blood pressure was 
higher in the elderly population as compared to the younger age group (p 0.019). 
However, no similar association was found for the diastolic blood pressure. 55% 
of the patients were receiving treatment for high blood pressure and despite that 
a significant number (73%) had systolic blood pressure more than 140mm Hg. 
The pattern of distribution of high blood pressure was uniform across all age 
groups, however, patients above 70 years of age were more likely to be on anti- 
hypertensive treatment as compared to those below 60 (p <0.001, chi-square 
test). There was no significant difference of systolic blood pressure in all groups 
between those who were on treatment and who were not. However the median 
values were higher than normal. This not only represent undiagnosed patients 
with hypertension but also those who were on medication, had inadequate 
control of high blood pressure. Elderly patients are more likely to have a 
significant past cardiovascular history and thus their treatment of risk factors is 
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more expected as compared to the younger population. Subsequent events are 
expected to be higher in the elderly population and not surprisingly, in this study 
we found a similar pattern of progression of PAD. 
The role of diabetes in relation to age in claudication is not clear. The distribution 
of diabetes in different age groups was similar in this study though insulin 
dependent diabetics were proportionally more in the younger age group. 
Claudication distances are expected to be higher in the younger patients. We did 
not notice such a difference in different age groups. It may be that the functional 
status of the patient is relatively more jeopardised than expected at a younger 
age as compared to the elderly. ABPI had an inverse relationship in relation to 
age. Gardner et al have reported a decline in ambulatory function and physical 
activity in patients 62 - 76 years of age based on their claudication distances at 
six months follow up despite no change in ABPI [240]. In our study infact the 
claudication distances improved across all age groups irrespective of the 
treatment with no significant change in ABPI. 
Smoking is a foremost risk factor in development and progression of PAD. 
Younger patients are more likely to be smokers as compared to the elderly and 
PAD is diagnosed up to a decade earlier in smokers than in non-smokers [46,48, 
51]. Smoking was a significant factor at any age in this series of claudicants. We 
also found that the smokers presented with claudication at an earlier age than 
those with history of no smoking. There was a significant association of current 
smoking to the younger age group as compared to those above 70 years of age 
(p < 0.001, chi-square test). Proportion of the current smokers decreased as the 
age increased and vice-versa. 
Patients are more likely to modify their lifestyle if faced with functional disability. 
In our series patients under 60 were more likely to give up smoking as compared 
to the elder groups. It may be explained by the attitude of the elderly to life and 
chronicity of the problem. 
Hyperlipidaernia has until now been treated as part the cardiac and other medical 
disease management only. Younger patients without a history of cardiovascular 
disease have not been seen as potential candidates for such a therapy. In our 
series we also found a similar trend. Cholesterol levels in age group 45 - 54 
were significantly higher as compared to other groups (p 0.022, chi-square test). 
On the whole 63% of the patients had a cholesterol level higher than 5.0 mmol/L. 
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TC: HDL ratio, which is thought to be a more sensitive marker of development of 
atherosclerosis, was significantly higher in the younger population (p < 
0.001, chi-square test). Overall the management of hyperlipidaernia was 
suboptimal and no age group was spared. With more awareness and current 
changing trends more and more people are now being offered statin therapy. We 
found an encouraging result at the end of the follow up as more patients from the 
lower age group were also offered the lipid lowering therapy. 
A similar pattern has emerged in terms of antiplatelet therapy. Again the elder 
patients especially those with a previous CAD or CVD history are more likely to 
receive antiplatelet therapy. Majority of the patients were taking antiplatelet 
therapy at six months regardless of age signifying a significant input from the 
hospital and primary care. 
Younger patients are economically more active and their interruption of daily life 
is going to weigh more in terms of intervention for symptomatic disease. 
Moreover the elderly population even with similar level of symptoms may be 
refused peripheral intervention especially surgery in presence of any significant 
morbidity. A similar pattern was observed in our study. Elderly population is more 
likely to suffer from a series of cardiovascular and other events. In our study we 
did not find any cardiovascular episode or death other than peripheral 
revascularisation occurring in the younger age group. 
Younger patients in the UK may be overlooked in terms of primary prevention 
and therefore may not be benefiting from the risk reducing agents like statins and 
antiplatelet agents. Awareness of this problem is highlighted following a specialist 
unit referral. Smoking and higher serum cholesterol levels appear to play a more 
significant role in the younger claudicants. These patients should be provided 
adequate support in this regard as this group was keener to give up smoking. 
Elderly patients have a higher morbidity and mortality especially from the 
cardiovascular disease. There is a need for higher input from the physicians for 
adequate primary and secondary prevention of any cardiovascular morbidity in 
this group. 
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Chapter 5 
Gender and peripheral arterial disease 
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5.1. Introduction: 
Little attention has been focussed on gender differences in PAD. This is known to 
have predilection for men [30,60,112,241]. Most studies report the prevalence 
of lower limb occlusive arterial disease to be lower in women than men [108, 
237]. The extended longevity in industrialized nations coupled with the expanding 
elderly female population is predicted to lead to an increase in the prevalence of 
this condition. In females PAD has a delayed presentation and consequently 
referral is delayed with treatment starting at a more advanced stage. 
5.2. Methods: 
474 consecutive patients with IC were recruited as per the inclusion criteria of the 
study to 23 vascular units across the United Kingdom. Sex was documented at 
the initial visit. Use of risk factor therapy was recorded at recruitment and at six 
month follow - up. Outcomes at the end of six months were documented and 
analysed. 
5.3. Results: 
The available data was analysed in relation to important variables for either sex. 
5.3.1. Age: 
In this study there were 159 / 474 (33.54%) were females and 315 / 474 
(66.46%) males. Median female age was 71.9 (range 40 - 87) while mean age in 
male population was 66.5 (range 34 - 93). Men were more likely to present with 
IC at an early age as compared to women (p <0.001, Kruskal -Wallis test). 
The sex distribution in different age groups is shown in fig 5.1. 
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Figure 5.1: Age disfribution as per sex. 
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Figure 5.2. Systolic pressure distribution as per gender. 
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Figure 5.3. Diasiolic pressure disiribution as per gender. 
(Diaslolicpressuregroips, 1ý<90,2-90- 100,3ý>100, *=Inissingvalue). 
Yes No 
NN 
Female 60.8 39.2 
Male 51.1 48.9 
0.04) 
Table 5.1. Treatmentfin- hypertension in either sex at initial visit. 
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5.3.2. Blood Pressure: 
The median blood pressure in the female population was 158 / 80 mmHg while in 
the male population it was 150 / 80 mmHg. Systolic pressure distribution pattern 
as per gender is depicted in figure 5.2. 
Similar distribution pattern was for diastolic blood pressure (figure 5.3). This 
pattern was proportionate to the representation of both sexes in this population. 
No statistically significant difference was noticed in systolic or diastolic blood 
pressure (p 0.15 and 0.49 respectively, Kruskal - Wallis test). 
5.3.3. Treatment for hypertension: 
The pattern of anti hypertensive treatment at the initial visit is shown in table 5.1. 
A higher proportion of females were on anti-hypertensive treatment (p 0.04, chi- 
square test). 
5.3.4. Claudication distance: 
In females the median initial claudication distance was 80 meters as compared to 
a median of 100 meters in males (p 0.019, Kruskal - Wallis test) at recruitment. 
While a similar pattern was seen in absolute claudication distance where the 
values were 109.5 and 150 meters for females and males, respectively (p 0.010, 
Kruskal - Wallis test). At follow-up, however, there was no difference in the 
median initial and absolute claudication distances i. e. 150 and 200 meters 
respectively, for both the groups (p 0.56 and 0.35, Kruskal - Wallis test). 
5.3.5. Ankle brachial pressure index: 
Median ABPI at recruitment for both genders was 0.63 while at six months it was 
0.65 for females and 0.67 for males. No significant difference was observed at 
six months (p 0.86,0.43 respectively, Kruskal - Wallis test). 
5.3.6. Lipid lowering therapy: 
There was no significant difference of treatment for hyperlipidaernia in both 
sexes (p0.97, chi-square test) at recruitment. Again at six months the proportion 
of either sex taking lipid lowering therapy did not change 
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Yes No 
M (%) 
Female 43.0 57.0 
Male 43.2 56.8 
(1) 0.97) 
Table 5.2. - Trealmenifiv hyperlipiduetnia in either sex. 
Yes No 
M N 
Female 17.1 82.9 
Male 18.4 81.6 
(P - 0.11). 
Table 5.3. Sex disiribution in angina. 
Yes No 
M) M 
Female 11.4 88.6 
Male 15.9 84.1 
(p 0.79) 
Tahle 5.4. Sex disIribution in myocardial infarclion. 
95 
significantly despite increase in total numbers taking such therapy (p 0.6, chi- 
square test). 
5.3.7. Previous Cardiovascular History: 
5.3.7.1. Angina: 
There was no dominance of one sex to another in regards to angina. Sex 
distribution in relation to angina at recruitment is shown in table 5.3. 
There was no significant association with either sex (p 0.72, chi-square test). 
5.3.7.2. Prior myocardial infarction: 
In patients with past history of myocardial infarction, sex pattern is shown in table 
5.4. Proportion of males with prior history of MI was slightly more than the 
females (15.9% vs. 11.3%) but this was not statistically significant (p 0.18, chi- 
square test). During six months follow up 5 more patients suffered from MI, of 
these 4 were males. 
5.3.7.3. Prior coronaty intervention: 
10 (6.3%) of the females and 32 (10.1%) of the males had previous history of 
coronary artery bypass grafting (CABG) while 6 (3.8%) of the females and 11 
(3.5%) of the males had undergone percutaneous coronary angioplasty (PTCA). 
During six month follow up 9 patients underwent coronary intervention, 7 of them 
being males. Overall there was no predominance of either sex in relation to 
coronary revascularisation (p 0.25, chi-square test). 
5.3.7.4. Prior Cerebrovascular accident (CVA): 
10 (6.3%) females and 24 (7.6%) males had prior history of CVA. Two further 
males developed CVA during six month follow-up. 
5.3.8. Diabetes mellitus (DM): 
9 (5.7%) of the females had insulin dependent diabetes (IDDM) while 16 (10.1%) 
had non-insulin dependent diabetes (NIDDIVI). 14 (4.4%) of the males had IDDM 
and 55 (17.5%) had NIDDM. There was no significant association of diabetes 
with either sex (p 0.10, chi-square test). 
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5.3.9. Smoking: 
Male and female distribution as per number of pack years smoked at recruitment 
is shown in table 5.5. 
There were 116 (73.42%) females with history of smoking (61 current and 55 ex- 
smokers) at the initial visit. Among the male population 297 (94.29%) had history 
of active smoking (138 current and 159 ex-smokers) (p <0.001, chi-square test). 
The median number of pack years smoked among females was 35 and for males 
40. This was statistically significant (p 0.002, Kruskal - Wallis test). This changed 
to 38 and 42 respectively at six months. 
At follow-up, 41.3% of the males were still smoking as compared to 33.3% of 
females. There was a significant relationship of male population to active 
smoking, past or present both at recruitment and at six month follow up (p < 
0.001 and p<0.001, respectively, chi-square test). 
Pack years smoked 
< 20 21-40 41-60 61 -80 > 80 
Female 27.4 34.6 27.4 5.3 5.3 
Male 16.2 34.6 30.8 9.4 9.0 
* values in percew 
Table 5.5. Sex distribution as per pack years s moked 
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5.3.10. Laboratory investigations: 
5.3.10.1. Cholesterol: 
The median cholesterol in the female population was 5.65 mmol/L (IQR 4.9 - 
6.4) while in the male population it was 5.3 mmol/L (IQR 4.4 - 6.1). The female 
population was likely to have a higher cholesterol level (p 0.007, Kruskal - Wallis 
test). 
The sex distribution as per cholesterol groups is shown in table 5.6. 
5.3.10.2. High-density lipoprotein(HU): 
The median HDL levels were 1.5 (lQR 1.3 - 1.8) and 1.3 mmol/L (IQR 1.1 - 1.5) 
for the female and male populations, respectively. These values were statistically 
higher in females (p < 0.001, Kruskal -Wallis test). 
5.3.10.3. Total Cholesterol/ HDL ratio (TCIHDL): 
The median total cholesterol / HDL ratio in the female group was 3.6 (IQR 2.7 - 
4.5) while in the males it was 4.0 (IQR 3.2 - 5.1). TC/HDL as contrast to 
individual values was significantly higher in the male population (p 0.026, Kruskal 
- Wallis test). 
5.3.10.4. Low density lipoprotein (LDL): 
The median LDL value in the female population was 3.1 mmol/L (IQR 2.4 - 3-7) 
and in the males, 3.2 mmol/L (IQR 2.2 - 4.0). There was no statistically 
significant difference (p 0.97, Kruskal - Wallis test). 
5.3.10.5. Other blood tests: 
Other relevant blood tests are shown in table 5.7. 
No significant differences were observed. 
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Sex Total cholesterol level 
(mmol/L) 
< 3.5 3.5-5.0 5.0-6.5 > 6.5 
Female 1.6 30.6 47.1 20.7 
Male 6.2 37.3 42.2 14.3 
* values in percent 
Table 5.6. - Total cholesterol distribution as per gender. 
Figure 5.6. Boxplol oflolal cholesterol as per gender. 
(Box represents the inferquarlile range and whiskers represent lhe range). 
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Test Female Male 
(median) (median) 
Haernoglobin 13.7 14.8 
(gm/dL) 
IVICv 91.2 91.1 
White cell 8.0 8.2 
count (*109/L) 
Platelets 276.0 237.5 
Glucose 5.1 5.4 
Creatinine 88.0 98.0 
Table 5.7. Other laboralory lesis in eilher sex 
Aspirin Clopidogrel Dipyridamole Ticlopidine 
Female 63.3 3.8 2.5 0 
Male 67.5 3.5 2.2 0 
Table 5. N. Pallern (#'wiliplafelef medicalion hi cilher sex. 
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5.3.11. Antiplatelet therapy: 
106 (67.1%) of the females and 225 (71.4%) of the males were on antiplatelet 
agents (p 0.33, chi-square test) at their initial visit. 32.9% females and 28.6% 
males were not taking any antiplatelet agent. By the time of follow-up, only 12.1 % 
of the females and 11.6% of the males were not taking antiplatelet therapy. 
Of those who were on aspirin, 92 (92%) females and 190 (89.2%) of males were 
using 75mg once daily. A similar pattern was noted at six months. 
There was no significant trend of distribution for taking or not taking antiplatelet 
medication based on gender. 
Reasons for not taking antiplatelet medication were almost similar (table 5.9). 
5.3.12. Peripheral Intervention: 
8.8% of the females and 6.7% of the males underwent peripheral 
revascularisation procedures. There was no significant trend in terms of gender 
for peripheral revascularisation (p 0.40, chi-square test). 
5.3.13. Events other than revascularisation: 
There was a similar proportion of either sex that suffered from cardiovascular or 
cerebrovascular events, amputation or death (5% females, 5.7% males; 
p 0.76, chi-square test). 
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22 Female 
DMale 
Figure j. 7 Gender-wise unliplatelel medicalion (in percentage) 
Female Male 
Never prescribed 18.6 20.3 
Allergy 00 0.3 
History of ulcers 3.8 2.6 
Indigestion 3.8 1.0 
Non-compliance 1.3 0.6 
Other 5.7 3.8 
vallies in percent 
Table 5.9. Reasonsfin- not itik ing antilVatelet inedicalion 
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Aspirin Clopidogrel Dipyridamole Ticlopidine 
5.4. Discussion: 
The role of major atherosclerotic risk factors in the development of PAD is 
somewhat similar in both men and women, however the relative risk is more 
favourable to women. With age this advantage diminishes in the female. There is 
limited data available to assess the cardiovascular risk factors which can explain 
the extent of observed sex difference in cardiovascular diseases. 
PAD often goes unrecognised in medical practice [242]. Leg pain on exertion 
and rest is a common complaint among females [243]. Hence often the diagnosis 
of PAD goes unnoticed particularly in the elderly female population. In our series 
men were more likely to present at an early age as compared to women. This is 
similar to other population based studies [30]. Similarly more men suffered from 
symptomatic PAD as has been found in other population based studies [22,23, 
27,36]. Atherosclerosis is a cumulative process, starting at a fairly young age. 
Even though sex differences like serum lipid profile and blood pressure 
disappear with age, it is possible that the cumulative effects of these risk factors 
on arteriosclerosis remain larger in men than in women, because of the longer 
exposure time in men. Higgins et al claim that contrary to earlier beliefs, the 
prevalence of PAD is similar in women and men and that women may have more 
asymptomatic disease [244]. 
Female gender has been associated with reduced clinical improvement in terms 
of claudication distance and ABPI over short term [245]. Our findings show a 
similar pattern at the time of recruitment; however improvement at six months 
was across the board irrespective of gender with no significant difference. 
Gardner has suggested that the shorter claudication distances in women with 
PAD are explained by their lower cardiopulmonary fitness and poorer self- 
perceived physical ability [246]. However we feel that with appropriate treatment 
this difference in exercise tolerance can be overcome as shown in this study. 
No statistical difference in terms of ABPI measurements was observed in the two 
groups. This parameter suggests that the functional impairment is independent of 
the ABPI measurement in the two genders. This has been attributed to greater 
leg strength in men [243]. Therefore, regular exercise therapy is recommended to 
improve the functional capacity of the caludicants especially in females. 
104 
Men are more likely to be smokers as compared to women. Also the number of 
pack years smoked was significantly higher in the male population. Smoking 
alone increases the development of PAD and this can be one of the major 
reasons for increased prevalence in the male population for a given age. 
Nilsson et al have reported a higher level of total cholesterol and HDL levels in 
women [247]. Total cholesterol increases with age. This increase usually levels 
out in the male population in the second half of the fifth decade while in the 
female population it increases till the age of 50 - 65 [248]. In this study female 
population had a higher cholesterol (p 0.007) a higher HDL level (p <0.001) and, 
hence, a higher TC/HDL ratio (p 0.02, chi-square). It appears that a higher HDL 
levels in the female population may offset the higher risk due to increased 
cholesterol level. TC/HDL ratio that is considered to be a more sensitive risk 
factor for development of atherosclerosis was found to be significantly higher in 
the male population largely due to low levels of HDL. Low HDL alone is a major 
determinant of the PAD risk and addition of smoking further decreases the HDL 
levels [249]. 
Females were more likely to be on anti-hypertensive therapy as compared to 
males. This can be explained by the fact that females tend to present with IC 
later in life than males. However no difference was found regarding lipid lowering 
therapy and antiplatelets in relation to gender. 
Women with PAD have been associated with a 2-4 fold increases in 
cardiovascular morbidity and mortality [244]. This may be related partly to late 
presentation of PAD among females. We found an overall 13.3% event rate in 
women as compared to 11.7% in men. Events other than revascularisation were 
not significantly different in the two groups at six month follow up (5% females vs. 
5.7% males). 
Men generally have a higher interventional rate without salvage indications as 
compared to women [246]. This difference in revascularisation could be 
secondary to lower prevalence of IC in women. Besides, smaller arterial diameter 
in the female population is likely to deter any interventional procedure as it is 
more prone to further complications [251,252]. However no such observation 
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was made in our series in this short period of time. A longer follow up will give a 
clearer picture on this aspect. 
Even though the major cardiovascular risk factors are the same in both sexes, 
preventive strategies like the use of HIRT in postmenopausal women has been 
proposed to reduce the risk of PAD [253]. Despite the card ioprotective effects, 
HIRT cannot be recommended for all postmenopausal women. Literature has 
provided conflicting evidence of its use in PAD and overall cardiovascular 
protection. Current evidence indicates potentially no benefit of combined 
estrogen-progesterone HIRT for primary or secondary prevention of vascular 
disease. Furthermore, HIRT may be associated with adverse clinical events and 
outcomes in certain women. Combination HIRT (estrogen-progesterone) reduces 
the beneficial effect of estrogens on coronary arteries, increases the progression 
of coronary artery atherosclerosis, increases the thrombotic potential of 
atherosclerotic plaques, and may significantly lower high-density lipoproteins, 
thereby decreasing the cardioprotective benefit of estrogen therapy. However, 
unopposed estrogen may provide some degree of vascular protection. 
Preliminary findings from current literature suggest that estrogen-only HIRT may 
be a beneficial treatment. This information merits additional research to assess 
the impact of estrogen alone on PAD. 
The problem of smoking, as emphasised earlier, should be more aggressively 
addressed in both sexes especially males. 
In conclusion, differences in major cardiovascular risk factors, particularly in HDL 
cholesterol level and smoking rate may explain a substantial part of the sex 
difference in PAD risk. 
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Chapter 6 
Six Month Follow Up 
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Introduction: 
As per the protocol of this observational study, patients were followed up at six 
months. This time interval allowed to check on the occurrence of any major 
clinical events such as the need for hospital admission, amputation or bypass, 
and any other treatments besides the assessment of QoL and comparison of 
variables with those of baseline data. 
6.2. Methods: 
All patients were given a six-month follow up date at their initial visit. However, it 
was appreciated at the time of protocol setting that some of the patients may not 
be able to attend the outpatients; therefore, a telephone follow-up was allowed if 
this was the case. 
435 (91%) patients were available for follow up. 64% visited the out-patients 
while 36% were contacted on telephone. Mean time to follow up was 200 (+/- 62) 
days. Objective parameters like blood pressure and ABPI were assessed where 
available. 
6.3. Results: 
6.3.1. Body Mass Index: 
The median body mass index at follow up was 26.19 (IQR 23.52 - 29.53) (n = 
337) as compared to baseline index of 26.02 (IQR 23.45 - 29.65) (n = 470). 
6.3.2. Systolic Blood Pressure: 
The median systolic pressure at six months was 150 mmHg (lQR 140 - 170) as 
compared to 152 mmHg (IQR 140 - 170) at the initial visit. Distribution of systolic 
blood pressures is shown in table 6.1. 
6.3.3. Diastolic blood pressure: 
The median diastolic pressure at follow up was 82 mmHg (lQR 76 - 90) as 
compared to baseline median of 80 mmHg (IQR 73 - 90). Further analysis is 
shown in table 6.2. 
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Systolic BP Baseline Follow Up 
(mmHg) n= 472 n= 276 
<140 30.8% 29.0% 
140-160 33.1% 38.4% 
160-180 24.2% 18.8% 
180-200 08.5% 08.7% 
200+ 03.4% 05.1% 
Table 6.1. Systolic bloodpressure disiribuiion tit baseline and 6 months. 
Diastolic BP Baseline Follow Up 
(mmHg) n= 470 n= 274 
< 90 83.2% 81.7% 
90-100 11.3% 13.9% 
> 100 05.5% 04.4% 
Table 6.2. Diastolic blood pressure pattern at base line an d6 months 
Baseline Follow Up 
Initial claudication 100 150 
distance ( m) (50-200) (50-300) 
[median(IQR)l 
Absolute claudication 150 200 
distance ( m) (75-250) (100-400) 
[median(IQR)] 
ABPI (Left) 0.71 (0.21) 0.74(0.21) 
[mean (sd)] 
ABPI (Right) 0.74(0.21) 0.78(0.22) 
[mean (sd)] 
Table 6.3. Claudictnionslants tit baseline and 6 months. 
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6.3.4. Claudication Status: 
Claudication distances and ankle brachial pressure indices at six months are 
shown in table 6.3. There was a significant difference in initial and absolute 
claudication distances (significant at 0.000 and at 0.000, respectively, Wilcoxon 
signed rank test) and also the ABPI (significant at 0.008, Wilcoxon signed rank 
test) at follow up. 
Patients undergoing peripheral revascularisation [35 / 474 (7.3%)] had a 
significant improvement of their initial and absolute claudication distances. For 
peripheral angioplasty it improved from the median initial distance of 40 meters to 
150 meters (significant at 0.001, Wilcoxon signed rank test) and for surgical 
procedures it improved from 100 meters to 300 meters (significant at 0.001, 
Wilcoxon signed rank test). Similarly the median absolute distances changed 
from 62.5 to 225 meters (significant at 0.001, Wilcoxon signed rank test) for 
angioplasty and 150 to 400 meters (significant at 0.001, Wilcoxon signed rank 
test) for surgical intervention. 
6.3.5. Smoking: 
At six months follow up, 159 / 409 (39%) were still smoking (figure 6.1). However 
there was no significant difference in the smoking status at follow up. 113 (59%) 
of the 192 current smokers at baseline attempted to stop smoking. Only 18/113 
(15.9%) were successful. Of these 52% used nicotine replacement therapy, 5% 
bupropion, 24% counselling and 34% resorted to various other methods. The 
median pack years smoked at six month follow up were 45.65 as compared to 
baseline of 43.08. 
6.3.6. Antiplatelet therapy: 
360/408 patients (88%) were taking antiplatelet treatment as compared to 70% at 
the initial visit (significant at 0.001, Wilcoxon signed rank test) (table 6.5). 92% 
were on Aspirin and 91 % of these were taking 75mg once daily. 48 (111 %) were 
still not taking any antiplatelet agent. 
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Figure 6.1. Smokingslalus al 6 inonihs. 
Baseline 
n= 473 
Current 42% 
Ex-smoker 45% 
Non-smoker 13% 
Table 6.4. Smokingstalus tit 0 and 6 months. 
Follow Up 
n= 410 
40% 
47% 
13% 
Baseline Follow Up 
n= 474 n= 408 
Aspirin 66% 81% 
Clopidogrel 4% 8% 
Dipyridamole 2% 2% 
Ticlopicline 0% 0% 
(P - 0.00/) 
Tuble 6.5. A nliplalelet it-end (it b aseline and 6 months. 
ill 
Nonsmoker 
13% 
6.3.7. Lipid lowering therapy: 
281/421 (67%) of the patients were on statins as compared to 208/474 (44%) at 
baseline (p < 0.001, chi-square test). 1% of the patients were on non-statins 
similar to initial visit. 
6.3.8. Lifestyle modification: 
Besides the conventional medical treatment, a proportion of the patients also 
underwent various lifestyle modifications. These are depicted in table 6.6. 
Other lifestyle modifications included non supervised exercise at home and 
gymnasium, dance club, attendance at risk factor clinic and vascular 
rehabilitation clinic, hypnosis, walking techniques, weight loss and getting written 
and verbal information on diet and exercise from clinician, nurse and internet. 
6.3.9. Drug history., 
Compared to baseline the medication pattern of patients is shown in table 6.7. 
There was no significant change in pattern of medication at six months apart 
from the statins as discussed above. 
6.3.10. Major Investigations: 
A number of patients underwent further investigations with a view to further 
evaluation and management. Major investigations performed were duplex 
scanning, peripheral angiogram, MR angiogram and coronary angiogram. This is 
shown in table 6.8. 
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Lifestyle change 
Smoking cessation class 17 
Exercise class run by the vascular unit 13 
Cardiac rehabilitation class 03 
Dietary advice from dietician 09 
Written advice on risk reduction 26 
Other 36 
Table 0.6. Lilýsfyle modýficafions employed duringsix nionihs. 
Baseline Percentage 
Drug (%) (%) 
Statins 44 69 
Non-statins 01 01 
Warfarin 04 06 
ACE Inhibitors 26 29 
B-blocker 18 18 
Ca-antagonist 23 24 
Anglotensin 11 07 06 
antagonist 
Nitrate 11 10 
Vasodilator 08 08 
Quinine 5 3 
Diuretic 29 33 
Oral hypoglycaernics 12 13 
Insulin 05 06 
HIRT 03 03 
Table 6.7. Medication pallerns (it initial visil and 0 month. fbIlow-up. 
113 
Investigation 
Peripheral duplex scan 
Peripheral arterial angiogram 
Coronary angiogram 
Magnetic resonance imaging 
Table 6.8. Xlqjor invesligalions peiJbi-ined in 6 monihs. 
Event 
All vascular events 
Death 
Non fatal MI 
Non fatal CVA 
TIA 
Congestive cardiac failure 
Table 0.9. Myjor events in 6 months since recruilmeni. 
Percent 
27 
34 
05 
03 
n (%) 
57(14%) 
17(4%) 
5(1%) 
2 (<l%) 
2 (<l%) 
3(1%) 
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Vascular Event n (%) 
Angioplasty / Stent 27(7%) 
Peripheral Vascular Surgery 7(2%) 
Amputation 1 (< 1 %) 
CABG 5(1%) 
PTCA 2 (< 1%) 
Table 6.10. Vascular inlervenlions in 6 inonihs 
6.3.11. Events since enrolment: 
Events were defined as any vascular event ending in radiological or operative 
peripheral revascularisation, amputation, non fatal MI, coronary revascularisation 
(CABG or PTCA), TIA, CVA and death. A list of major events occurring over a 
period of six months is displayed in table 6.9. 
Interventions and revascularisation procedures in the first six months of 
enrolment were-. 
There were in total 64 hospital admissions. These were not only for vascular 
reasons but also for a number of medical conditions. 
6.4. Multivariate analysis: 
Multivariate analysis was carried out to assess the impact of different risk factors 
in relation to development of events. 
These are summarised on the following page. 
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Variable 
Age 
Sex (% male) 
APBI 
Systolic BP 
Diabetes 
Rx hypertension 
Prior CHD (%) 
Vascular No vascular p 
event event 
(n = 58) (n = 473) ch i2 
< 60 12(21%) 94(23%) 0.58 
60-70 22(38%) 129(31%) 
> 70 24(41%) 192(46%) 
37(64%) 278(68%) 0.63 
< 0.3 6(10%) 4(1%) 0.003 
0.3-0.5 11 (19%) 65(16%) 
0.5-0.7 25(43%) 191 (47%) ns 
0.7-0.9 16(28%) 146(36%) ns 
< 140 22(38%) 123(30%) 0.015 
140-160 24(41%) 132(32%) 
160-180 11 (19%) 102(25%) ns 
180 -200 1(2%) 39(9%) ns 
> 200 0(0%) 16(4%) ns 
14(24%) 79(19%) 0.18 
31 (53%) 226(54%) 0.88 
27(47%) 109(26%) 0.002 
Antiplatelet use (%) 45(78%) 286(69%) 0.17 
Lipid lowering therapy use (%) 31 (53%) 180(43%) 0.15 
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Variable Vascular No vascular p 
event event 
(n = 58) (n = 473) ch i2 
Absolute claudication distance < 50m 16(28%) 62(15%) 0.25 
50-1 00m 13(23%) 99(24%) ns 
100-200m 15(26%) 119(29%) ns 
200-300m 5(9%) 64(16%) ns 
300-400m 3(5%) 29(7%) ns 
> 400m 5(9%) 35(9%) ns 
Smoking Current 24(41%) 174(42%) 0.53 
Ex-smoker 24(41%) 191 (46%) ns 
Non-smoker 10(17%) 50(12%) ns 
Total Cholesterol (mmol/L) < 3.5 3(7%) 13(4%) 0.86 
3.5-5.0 16(36%) 103(34%) ns 
5.0-6.5 18(40%) 136(45%) ns 
> 6.5 8(18%) 48(16%) ns 
13 not checked 113 not checked 
TC / HDL < 3.0 7(23%) 34(23%) 0.58 
3.0-4.5 11 (37%) 68(46%) ns 
> 4.5 12(40%) 46(31%) ns 
*28 not checked *267 not checked 
Table 6.11. Afullivariale analysis in relation Io till vascular evenis. 
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All vascular events: (Table 6.11) 
Multiple variables analysed in relation to the outcome, in this case events as 
described earlier. A low ABPI and a history of coronary heart disease were 
significantly associated with any form of event.. 
6.4.2. Death: (Table 6.12) 
Advanced age, a low ABPI, a previous CHID history and a high TC / HDL ratio 
were significantly associated with death. 
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Variable Death No death P 
(n = 13) (n = 469) 
Age < 60 0(0%) 105(23%) 0.014 
60-70 3(23%) 146(32%) - 
> 70 12(77%) 205(45%) - 
Sex (% male) 13(77%) 303(66%) 0.41 
APBI < 0.3 1 (8%) 9(2%) 0.007 
0.3-0.5 5(38%) 71 (16%) 
0.5-0.7 5(38%) 212(47%) ns 
0.7-0.9 2(15%) 160(35%) ns 
Rx Hypertension 7(54%) 249(55%) 0.95 
Prior CHD (%) 8(62%) 127(28%) 0.013 
Antiplatelet use (%) 11 (85%) 317(70%) 0.21 
Lipid lowering therapy use (%) 7(54%) 202(44%) 0.49 
Absolute claudication distance 
< 75m 4(25%) 95(24%) 0.56 
75-150m 7(44%) 113(28%) 
150-250m 2(13%) 92(23%) 
>250m 3(19%) 98(25%) 
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Variable Death No death p 
(n = 13) (n = 469) 
Smoking Current 4(31%) 192(42%) 0.22 
Ex-smoker 5(38%) 208(46%) ns 
Non-smoker 4(31%) 56(12%) ns 
Total Cholesterol < 3.5 0(0%) 16(5%) 0.74 
3.5-5.0 4(50%) 115(34%) ns 
5.0-6.5 3(37%) 152(45%) ns 
> 6.5 1 (13%) 55(16%) ns 
5 not checked *123 not checked 
TC / HDL < 3.0 0(0%) 41(24%) 0.018 
3.0-4.5 1 (20%) 79(45%) ns 
> 4.5 4(80%) 54(31%) ns 
*8 not checked *287 not checked 
Table 6.12. Mullivariale analysis in relation to death, MI and C VA. 
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6.5. Discussion: 
Follow up of this cohort of patients allowed an assessment of the progression of 
IC, documentation of various clinical outcomes and practice patterns. Role of 
various risk factors in relation to IC also came under review. Management of the 
claudicants following initial visit allowed to document the current hospital based 
practice patterns. 
Atherosclerotic risk factors are common in patients with PAD. However, the 
intensity of lifestyle modification and the use of evidence-based medical therapy 
in this high-risk cohort remain suboptimal. There is a significant opportunity to 
improve the appropriate use of secondary preventive therapy in these high-risk 
patients and improve patient compliance with education and empowerment. Six 
month follow up allowed us to study this aspect across the UK. 
Hypertension as discussed in sectionl. 4.3. is associated with 2-3 fold risk of PAD 
and is associated with severe disease [39]. We found inadequate management 
of hypertension in this group over six months. Systolic BP was more than 140 
mmHg in 71% at six months versus 69.2% at baseline while diastolic pressure 
above 90 mmHg was 18.3% versus 16.8%. As management of hypertension is 
generally considered to fall under the domain of a general practitioner and 
physician, therefore, most of the times its management is not altered by the 
vascular units. Hence no change in blood pressure readings at six months audits 
the trends of management at general practice level rather than the specialist 
vascular centre. A persistent high blood pressure reading is a worrying trend and 
calls for effective communication between the general practitioner and the 
vascular unit. 
Smoking is a major risk factor not only in development of PAD but also in its 
progression (see section 1.4.1). At six months follow up 40% of the patients were 
still smoking as compared to 42% at recruitment. It appears that every patient 
was conveyed the message to stop smoking as more than half (59%) of the 
current smokers did attempt to give up smoking. However complete cessation 
results were disappointing. Although verbal advice was provided in most cases, it 
was not followed up with further supportive actions. Persistent and more 
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intensive support is required in this group of patients. Patient's compliance with 
any treatment aimed at secondary prevention always remains a significant 
problem. Any lack of support is enough reason for the patients to carry on their 
normal lifestyle. 
Diabetes is well associated with disease progression and complications. In this 
series it did not show a significant pattern of progression of disease or higher risk 
of complications than the non-diabetics at six months. This is similar to findings 
of the Framingham and Strong Heart studies [26,248]. 
Heart protection study has highlighted the role of statins in prevention of serious 
cardiovascular complications [68]. Statins have been associated with improved 
walking distances [176]. This message seems to be getting across as lipid 
lowering therapy increased from 44% to 69% (p <0.001) at six months in our 
series. Improvement in exercise tolerance partly may have resulted from use of 
such a therapy. 
As mentioned earlier lipid measurements were being done routinely only in 14 of 
the 23 centres at the initial visit. Patients on lipid lowering therapy had lower 
cholesterol and LDL levels as compared to those without such therapy (total 
cholesterol 5.0 vs. 5.8 mmol/L and LDL 2.7 vs 3.5 mmol/L, p<0.001). At follow 
up lipid profile was not recorded though these were not routinely checked at most 
centres. Most of the patients receiving lipid lowering therapy were on simvastatin 
20mg per day. Currently in view of heart protection study the recommended dose 
is 40mg. This may explain the inadequate control of lipid profile and thus limited 
benefit of such therapy. Caution should be exercised in patients with hepatic 
dysfunction or myalgia. Liver function test and creatine kinase should be checked 
in symptomatic patients. Routine liver function tests measurement has not 
recommended [68]. 
This trends needs attention as patients with IC may be denied of the benefit of 
lipid lowering therapy especially when this group is a high risk for future 
cardiovascular morbidity. Checking cholesterol routinely may also help to not 
only diagnose but follow these patients and assess the benefit of lipid lowering 
therapy. 
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Over 70% patients were counselled and underwent various lifestyle 
modifications. Although general advice was available, there was a noticeable 
lack of uniform package for further counselling for smoking cessation, risk factor 
modification and supervised exercise programmes. 
Dormandy has pointed out that the majority of claudicants tend to stabilise or 
improve over a period of time [229]. It was not surprising to find that the median 
initial claudication distances increased over six months (initial CID 100 versus 150 
p<0.001, absolute CID 150 versus 200 p <0.001). This symptomatic stabilisation 
or improvement may be explained by changes at cellular level and development 
of local compensatory mechanisms and also improvement in modification of risk 
factors and lifestyle of the patients. 
PAD Antiplatelet Consensus Group has recommended that all patients with IC 
should be on an antiplatelet agent for long term [234]. Hirsch et al have reported 
antiplatelet use of 33% only in newly diagnosed patients with PAD as compared 
to 54% of known PAD patients in a survey of 6979 patients across the United 
States [29]. We observed a significant improvement in antiplatelet use in our 
series at six months (88% versus 70%, p 0.001). This signifies an increasing 
awareness on part of the different health professionals involved in the 
management of PAD. 
In this study a relatively high percentage of patients underwent further imaging, 
i. e. 27% had a duplex scan and 34% underwent peripheral angiogram. This is 
explained on the basis of a local practice pattern at one or two participating 
centres rather than a universal pattern. This may represent a regional trend in 
terms of patients' characteristics, disease severity or the varied management 
trend in a few institutions. 
Frequency of local intervention varies widely from 3% to 22% in different studies 
[134,135]. As discussed earlier (section 1.6.1.3. ) only one fourth of all patients 
with IC deteriorate progressively, with an intervention rate of approximately 5% 
over 5 years for either severe claudication or deterioration to critical limb 
ischernia [30]. However in our series within a timescale of six months only, 7.8% 
of patients underwent peripheral intervention (angioplasty 6.2%, surgery 1.6%). 
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These patients either had troublesome claudication or were treated as per the 
treatment centre's policy of early intervention. Low ABPI, absolute claudication 
distance and number of pack years smoked were more likely to be associated 
with peripheral revascularisation. These varying policies call for uniform 
intervention indications as this will not only help to compare the results of 
different regions but also allow the cost implications in the management of PAD 
at national level. 
Low ABPI, high systolic pressure and prior CHD were significantly associated 
with development of all vascular events. 14% of the patients suffered from a 
vascular event during a short period of six months. An inverse relationship was 
also observed between ABPI and the development of cardiovascular events. 
Similar results have been reported by the Framingham Offspring Study and the 
Cardiovascular Health Study [39,111 ]. These findings confirm the usefulness of 
the ABPI as a useful marker of generalized atherosclerosis as observed in other 
studies [23,254]. 
2- 4% of patients with IC are expected to develop a nonfatal cardiovascular 
event within the first year [30]. In this series 2.1% presented with a nonfatal MI, 
CVA or TIA and 1.6% underwent coronary revascularisation within six months. 
50 - 80% of the PAD patients die due to cardiovascular events [138,139]. 13 
patients died during the six month follow-up. 60% deaths were related with 
cardiovascular events. Besides low ABPI, age, high systolic blood pressure and 
prior CHD were significantly associated with death, MI or CVA. 
National cardiac guidelines recommend that patients with IC should be managed 
in the same way as those with established coronary heart disease [251]. Cassar 
et al have reported a sub-optimal management of major risk factors in 
claudicants by the vascular surgeons in the UK [256]. Routine laboratory risk 
factor profile is not being checked at the referral centres and the chance to detect 
and manage new cases or cases with uncontrolled diabetes or hyperlipidaemia 
are being missed or sub-optimally managed. 
Claudication improves with conservative measures in the majority of patients 
over a period of time. However, PAD patients are under treated for risk factors as 
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compared to CAD and CVD. This is especially so at the primary care level. There 
is a need for guidelines for uniform management of IC. Provision of a national 
risk reduction programme and life style modification package is urgently needed 
for this group of high-risk patients. 
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Chapter 7 
Quality of life 
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7.1. Introduction: 
Symptomatic disease of any sort often leads to diminished QoL (QoL) and PAD 
is no different. The symptoms of PAD are especially likely to persist over a 
prolonged period and this limited functional status limits the functional capacity 
significantly as compared to the healthy population [257]. Claudication not only 
limits the distance walked but also results in substantial impairment of social 
functioning, emotional and mental health [258,259]. This limitation in QoL is only 
partially determined by the severity of walking limitation as the presence of 
cardiac and associated morbidity also plays a role in IC [260]. 
QoL has become increasingly important as an outcome measure in PAD 
because any interventional or conservative treatment should be aimed at 
improving the quality rather than just the quantity of life. Clinicians predict the 
QoL of claudicants less accurately than patients do themselves [258,261]. 
Hence, several measurement tools are available to look objectively at any 
change in QoL status. The instruments used for measuring health-related QoL 
are expected to be valid (ability to measure what it is supposed to measure), 
reliable (reproduce a stable pattern of scores), feasible (easy to answer and 
administer for the respondent and investigator, respectively), responsive (ability 
to detect a clinical change or treatment effect) and to have cultural and language 
adaptations such as standardised translations, linguistic evaluations and 
attention to cultural issues. 
7.2. Quantification of QoL: 
QoL measures can be broadly divided into two groups: 
a) generic 
b) disease - specific 
7.2.1. Generic Health Status Questionnaires: 
Generic instruments tend to measure the global QoL dimensions, generally 
looking at 
9 functional status - ability to perform routine daily activities, 
-P perceived health - patient's perspective of his/her current health status, 
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" psychological status - patient's mental response to his/her present 
disease, 
" role function - ability of a patient to perform his obligatory duties. 
These tools may overlook the specific effects of the disease on QoL and thus 
may not detect any subtle though important variations. These also do not analyse 
disease specific symptoms [262]. However the principal objective of using the 
generic measures is that these allow comparison of the results of treatment 
across different diseases and also are useful for comparing different treatments 
in Health Ecomonic analysis. 
Various generic tools for measurement have been developed. The following 
have commonly been employed in vascular studies: 
> Euro Qol (EQ5D) 
> Medical Outcomes Study Short-Form 36 (SF-36) 
> RAND - 36 
> Sickness Impact Profile (SIP) 
> McMaster Health Index Questionnaire (MHIQ) 
> Functional Status Questionnaire 
> Health Utilities Index (HUI) and utilities (HU12 and HUB) 
> Nottingham Health Profile (NHP). 
7.2.2. Disease-specific Questionnaires: 
A disease-specific health status questionnaire is generally used to measure 
baseline disease-specific health status. It concentrates on QoL domains affected 
by the symptoms of the disease in question. These are also used to measure any 
changes in the symptomatic disease. Disease-specific are more responsive [262, 
263]. A number of these have been used in different centres to measure the 
patient oriented outcomes. 
Walking Impairment Questionnaire (W[Q) 
Peripheral Arterial Questionnaire (PAQ) 
VascuQol 
Physical Activity Recall 
Claudication Scale (CLAU-S) 
CCCQ (Charing Cross Symptom Specific Questionnaire) 
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Artemis (Assessment of QoL in lower limb arteriopathy) 
Intermittent Claudication Questionnaire (ICQ) 
ECQ (Edinburgh Claudication Questionnaire) 
PAVK-86 [264] and 
Spitzer QL-index (a combined generic- and disease-specific 
questionnaire). 
7.3. Methods: 
In this study the generic QoL tool Euroqol -5 (EQ-5) and the specific QoL tool 
the Peripheral Arterial Questionnaire (PAQ) were employed at the time of initial 
visit and then at the follow up. The patients generally answered these 
questionnaires independently. Where any help was required the patients were 
given an adequate explanation. 
The EuroQol (EQ-5) is a 5-item questionnaire that can be used to measure 
health utility and health related QoL [218]. The EQ-5 defines health in five 
dimensions (mobility, self-care, usual activities, pain and discomfort, and anxiety 
or depression). In each dimension a respondent can belong to one of three 
categories-no problem, moderate problem, or severe problems. A utility value is 
therefore ascribed to an individual's health state based on the absence or 
presence of moderate or severe problems in the five dimensions. The EQ-5 also 
has a visual analogue scale that enables respondents subjectively to assess their 
health on a scale ranging from 0 (worst possible health state) to 100 (best 
possible health state) (see appendix 3). 
Each of the five dimensions is divided into the levels of perceived problems: 
Level 1: No problem 
Level 2: Some problem 
Level 3: Extreme problem 
Each health state was defined by combining one level from each of the five 
dimensions. These health states were converted to scores using the values 
based on the data collected from a representative survey of the UK general 
public. 
The visual scale analogue "Thermometer" generated a self-rating current health- 
related QoL. This had end points at top of 100 (best imaginable health state) and 
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at bottom 0 (worst imaginable health state). Each respondent rated the health 
status by drawing a line from the box marked "Your own health state today" to 
the appropriate point on the "thermometer" scale. 
PAQ is a recently validated, disease specific related QoL questionnaire with 21 
items in 5 domains of patient symptoms, physical and social limitation, treatment 
satisfaction and QoL, specific to peripheral arterial disease (see appendix 3). The 
PAQ is scored by assigning 1 point to the response suggesting the most limited 
function and an additional point for each higher response in the item. Scale 
scores are generated from summing the individual items within a domain and 
subtracting the lowest possible score for that domain, dividing by the range of 
that domain and multiplying by 100. All domains range from 0 to 100, where 
higher scores indicate less physical limitation, fewer symptoms, greater treatment 
satisfaction, or better QoL. Combining the physical limitation, symptom 
frequency/burden, social function, and quality-of-life domains derives a summary 
score. 
These questionnaires were repeated at six-month interval at the follow-up visit. 
7.4. Results: 
7.4.1. Euroqol - 5. (Table 7.1) 
The EQ -5 generated profiles that can be measured against the important risk 
factors. Overall limitations of usual activities, pain or discomfort and anxiety or 
depression were of more concern than mobility and self care. The median health 
score was 0.69 (IQR 0.59 - 0.73) and self reported health status was 65 (IQR 50 
- 76) on a scale of 0- 100 at the initial clinic visit. 
At follow-up the median health score was 0.69 (IQR 0.62 - 0.76) (p < 0.0013, 
Mann -Whitney test) and median health status 'thermometer' was 70 (IQR 50 - 
80) (p 0.037, Mann - Whitney test). 
Mobility and pain were the most commonly reported domains that affected the 
QoL. 
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Dimension No problem Some problem Extreme problem 
N N N 
0 month 6 month 0 month 6 month 0 month 6 month 
Mobility 7.4 19.8 92.4 79.7 0.2 0.5 
Self Care 90.4 90.2 8.9 9.5 0.7 0.3 
Usual 35.9 48.8 59.9 44.6 4.2 6.6 
activities 
Pain / 7.2 20.1 70.6 68.1 22.2 11.8 
Discomfort 
Anxiety / 63.6 66.7 32.2 27.8 4.2 5.5 
Depression 
Table '/. I Distribution patiern o/'/(! i, (! / qI'disahility qfthefive /ý/e domains al inilial 
visil and a/ six months. 
(Values are quanlýfied EQ -5scores. fi)r each domain). 
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Figure 7.1. Distribution (? I'eziroqol -- 5 domains tit inilial visit as per age group. 
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7.4.1.1. Age: 
The life quality profile generally appears to remain unchanged in relation to age. 
No significant differences were observed in the three age groups in relation to 
different life quality parameters. 
Interestingly the EQ -5 scores were better in the above 70 years group as 
compared to below 60 (p 0.003, chi-square test). Self reported health status 
scores were not significantly different in the three age groups: 65,70,70 were 
the median scores in <60,60 -70, > 70, respectively. 
At follow-up EQ -5 scores were 0.69,0.69 and 0.69 and 'thermometer' means 
were 70,70 and 65 for age groups < 60,60 - 70 and > 70, respectively. These 
were not statistically significant for each age group. 
7.4.1.2. Sex: 
The median health status scores were 0.66 and 0.69 for female and male at 
recruitment (p 0.058, Kruskal - Wallis test) and 0.69 for both at follow-up. Self 
reported health status medians were 60 and 65 (p 0.035, Kruskal - Wallis test) 
on the thermometer scale at initial visit. These were 65 and 70 (p 0.40, Kruskal - 
Wallis test) for female and male, respectively, at six months. 
Only self reported health status scale had some significance at the initial visit in 
relation to gender. 
7.4.1.3. Claudication: 
Claudication distance was strongly related to QoL at recruitment and at six 
months. EQ -5 scores showed ap value at recruitment for initial CID 0.004, for 
absolute CD 0.016 and at follow - up this was < 0.001 for initial CD and 0.025 for 
absolute CD. Similarly 'thermometer' scale values were highly significant in 
relation to claudication distances. 
ABPI did not show a statistical significance in relation to health scores at the 
initial visit of follow up visits (p 0.85 and p 0.29, Kruskal - Wallis test). Similarly 
self reported health status scores (thermometer) did not correlate with ABPI 
value at recruitment or follow up visit. 
Health scores in patients with bilateral claudication were not significantly different 
as compared to unilateral claudicants except for the self reported 
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Figure 7.2. Disiribulion ofhealth related domains (in percent) as per gender (it 
recruilmenl. 
Bilateral 
claudication 
No 
Yes 
Score 
(median) 
0 month 6 month 
Thermometer 
(median) 
0 month 6 month 
0.69 0.69 69 60 
0.69 0.69 70 65 
Table 7.2. QoL in relation to uni- or hi-laleral claudicalion. 
E-1 Female 
LiMale ý 
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health status at the initial visit when these were found to be low in patients with 
bilateral claudication (p 0.017, Kruskal -Wallis test) (table 7.2). 
7.4.1.4. Smoking: 
Smoking status had again no significant effect on the QoL. Health scores (p 0.36 
at 0 month, p 0.32 at 6 months, Kruskal - Wallis test) and self reported health 
status scores (p at 0 month 0.34, p at 6 months 0.65, Kruskal - Wallis test) did 
not reveal any significant correlation with the smoking status of the patient. Again 
the number of pack years smoked had no bearing on QoL status. 
7.4.1.5. Intervention: 
Peripheral revascularisation had a positive impact on QoL with scores improving 
from 0.48 to 0.50 for angioplasty and 0.70 to 0.86 for surgical intervention (p 
0.005, chi-square test). Similarly 'thermometer' score improved from 62.8 to 67.9 
for angioplasty and 58.8 to 77.0 for surgery (p < 0.001, Chi-square test). 
7.4.1.6. Others: 
Use of any medication or any blood investigation was not related to any 
significant change in QoL. Also, there was no effect of minimum school education 
as compared to more educated on different measures of life quality at baseline 
and at follow-up. 
7.4.2. Peripheral artery questionnaire (PAQ): 
PAQ was conducted in 338 (81.8%) patients at baseline and 299 (63%) at six 
months. In 287 (60.5%) patients this was conducted both at recruitment and at 
follow-up. 
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Domain Baseline Follow-up Mean 
mean value mean value difference 
Phvsical 34.2 38.8 4.6 
I 
limitation 
Symptom 41.4 50.1 
burden 
Symptom 36.7 45.7 
stability 
Social 48.2 51.7 
limitation 
Treatment 81.8 77.7 
satisfaction 
QoL 43.8 53.2 
Summary 42.2 48.0 
Score 
Table 7.3. PAQ. vcores tit baseline andjbllow, ip. 
p 
0.001 
8.7 < 0.001 
9.0 < 0.001 
3.5 
-4.1 
9.3 
5.8 
0.007 
0.005 
< 0.001 
< 0.001 
Age group Mean summary score Mean summary score 
at baseline at follow-up 
< 60 37.4 46.7 
60-70 44.6 48.4 
> 70 42.8 49.3 
Table 7.4. Meansummary scores a/ haseline andfi)llow-up. 
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7.4.2.1. Age: 
The mean summary scores for each of the age group are displayed in table 7.4. 
Distribution pattern of various domains as per age group is shown in the figure 
7.4. 
7.4.2.2. Sex: 
The mean (+/- sd) summary scores for female at baseline and follow up were 
38.9 (+/- 18-6) and 45.6 (+/- 20.9); for male these were 43.7 (+/- 19.0) and 50.0 
(+/- 22.6). The summary scores were not significant in relation to sex at baseline 
and follow-up although the mean scores were higher in males (p 0.056 and 
0.121). The change in scores was significant in both sexes at follow-up in 
comparison to baseline. 
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7.4.2.3. Claudication: 
Initial and absolute claudication distances had a positive correlation with 
summary score of PAQ (p < 0.001) at baseline. Similarly this correlation was 
significant at follow-up (p < 0.001). Regression analysis also showed significance 
between ABPI and summary score at recruitment (p 0.006) and at follow-up (p 
0.027). Although the summary scores were less for the bilateral claudicants as 
compared to unilateral claudication, these were not statistically significant (p 
0.06). 
7.4.2.4. Smoking: 
Smoking status scores at baseline and at six months had no impact on the PAQ 
scores. All the groups benefited over six months however, non-smokers had the 
maximum benefit in term of improvement in QoL. 
There was no significant benefit of quitting the smoking over a short period in 
terms of improvement in QoL as the change in mean scores was not significant. 
7.4.2.5. Peripheral intervention: 
Peripheral intervention had a positive impact on summary scores. These 
changed from 44.3 to 69.7 for surgical intervention and from 30.6 to 45.6 for 
angioplasty (p < 0.001). 
7.4.3. EQ -5 and PAQ: 
There was significant association of the scores of EQ -5 and PAQ both at 
recruitment (p < 0.001) and at follow up (p < 0.001). Similar was true for the 
I 'temperature scale of EQ - 5. 
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7.5. Discussion: 
As discussed earlier IC not only limits the blood flow to the lower limb but also is 
an indicator of systemic atherosclerosis. Hence it exerts a global impact on the 
patient. This impact besides the limited ambulatory disability, also translates into 
generalised decreased functional capacity. Using generic and disease specific 
QoL instruments this functional disability can be quantified. The use of both 
clinical and patient-based - parameters is essential to assess the complete 
outcome of management of claudication. Generally clinical outcome measures 
have been used to evaluate the efficacy of any treatment but these appear to 
have a poor correlation with QoL measures [265,266]. Barletta et al have shown 
a significant impairment of general health and low scores for physical and 
emotional dimensions in patients with IC as compared to controls [262]. This 
study confirms these findings with general QoL scores on EQ -5 scales were 
0.55 (range 0.05 - 1.00) and 63 (range 0 -100) at the initial visit. On the PAQ 
scale the summary score was 42 (range 0- 100) at recruitment. 
PAD patients have generally performed poorly on QOL measurement scales 
[267,268]. Limitation of daily physical activity in performing routine activities and 
pain are the major dimensions in patients with IC that effect the QoL [269]. 
However depression is also common [270]. Patients rate their health status 
approximately one third lower than the perfect health state. Self reported health 
status in our series was 63 at recruitment. 
Claudicants have greater perception problems in the areas of energy, pain, 
emotional reactions, sleep, and physical mobility [259]. Pain and mobility were 
the main domains that had a bearing on QoL in this series. Physical and social 
limitations and the symptom burden on PAQ scale were the main domains 
affecting the QoL. 
In clinical practice objective disease criteria may not be an appropriate tool to 
assess the QoL in PAD patients. Uwe MQlIer et al have reported that QoL in PAD 
patients is independent of the peripheral Doppler pressure and the angiographic 
severity of the disease [271]. The most important criterion is the functional 
disability. However the same study concludes that the absolute claudication 
distance and body mass index are the most predictive variables for the QoL. 
impairment in QoL in patients with IC correlates poorly with the reduced exercise 
capacity assessed by, the treadmill test [266]. In our series we did find a 
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significant direct association of QoL scores with that of exercise tolerance. These 
scores had variable correlation with the ABPI. Any conclusion drawn on QoL 
from ABPI measurements would be inappropriate. A correlation has been 
established between the clinical indicators and QoL but not sufficient to assume 
that variations in clinical indicators result in reciprocal variations in QoL [265]. 
Patients over time become well equipped with the knowledge and understanding 
of the disease process. They tend to adjust or adapt to the problems faced in 
relation to claudication. This helps in the improvement of QoL. In this study we 
report an improvement of QoL measurements in a majority of patients over a six- 
month period regardless of the management format. There were significant 
improvements in health related QoL scores, both generic and disease specific, at 
six months. This can be related to overall lifestyle and overall risk factor 
modifications in this cohort over a six-month follow up. 
Supervised exercise programmes have shown to increase the walking distance 
[155,162,163,272]. Exercise is usually advised to patients with IC. In a recent 
study, QoL scores employing SF-36 and Charing Cross Symptom Specific 
Claudication Questionnaire (CCCQ) were significantly better in patients with 
supervised exercise than the advice group alone at 9 months (43% vs. 16%, p 
<0.05) [273]. Tsai et al have reported an improvement of perception of health- 
related QoL from 12% to 178% on a 12 week supervised exercise programme 
[274]. A Swiss study reports similar results with pain, mood and functional status 
subscales on PAVK-86 improving significantly in patients with IC after 12 week 
exercise training [275]. 
One may predict that an older population might have a poor QoL not only from 
claudication but also from other co-morbid pathologies. We found significantly 
low scores at baseline in less than 60 year old patients as compared to older 
people but this levelled at six months follow up. Claudication perhaps limits the 
life pattern more in a young active patient. Claudication and PAD have a greater 
impact on women than on men and may result from the higher prevalence of 
mood disturbance and bodily pain reported by women [276]. Despite the 
similarity in disease severity, women have decreased physical functioning, more 
bodily pain and greater mood disturbance [276]. A recent study reported a 
statistically significant reduction in QoL of young women with PAD [271]. All 
domains of RAND-36 in comparison with QoL in healthy age-matched control 
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subjects were found to be diminished in this group. In another study male gender 
was associated with better scores for energy and fatigue, and for sleep and rest 
[260]. However, in our series we did not find a significant difference at 
recruitment or at follow up though mean scores were higher in males. Females 
were more anxious or depressed on EQ -5 scale and had difficulty in social 
interactions as compared to males (p 0.014). 
Smoking increases PAD progression. Quitting smoking may not only slows this 
progression but is expected to improve the QoL. We did not find a significant 
difference in QoL among current or ex-smokers and non-smokers over six month 
follow up. Cessation of smoking for a short period of time had no impact on QoL 
scores. However, improvement in non-smokers' QoL was much more than those 
with history of smoking over a six-month period. 
Pharmacotherapy may have a positive impact on QoL. Cilostazol, naftidrofuryl 
and prostaglandin El have been shown to improve the QoL in claudicants [201, 
211,277,278]. Statins have been reported to increase the walking ability in 
patients with IC but were not associated with improvement of QoL measures 
[276]. We did not observe any association of medication patterns with 
improvement in QoL scores. The effect of 'claudication improving' medicines, like 
cilostazol was not assessed in our study. 
Many studies of invasive procedures have also been reported to have variable 
effects on QoL[280-282]. In our series we observed a very clear and positive 
impact of revascularisation procedures on the patient centred outcomes. EQ - 
5's health and 'thermometer' scores and PAQ's summary scores improved 
significantly following angioplasty or surgical intervention. Whilst not surprising, 
this data might support the value of such intervention in PAD. Improvement of 
mobility with no claudication explains this better QOL scores. 
For the success of any management plan, it is important to consider the patient 
centred outcomes as well. This may be the ideal outcome of any management 
plan. Physicians in charge of the care of claudicants should have a thorough 
understanding of the specific and overall effects of IC so that they can develop 
therapeutic plans suited to individual needs. Mobility may be an important aspect 
for a young claudicant in order to pursue his or her career while an elderly patient 
with a similar level of disease may not have any deterioration in QoL. Successful 
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management outcomes must therefore include the patient centred outcomes. A 
uniform strategy in this regard is suggested at a national level. The results of 
such outcomes may be more easily comparable than for complex clinical 
parameters. 
142 
Chapter 8 
Conclusions 
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The risk factors for PAD are well defined; however, the management of these risk 
factors and the overall management of PAD remains variable, not only at the 
primary care level but also in specialist vascular units. IC is the major form of 
presentation of this disease. We studied 474 claudicants from 23 centres across 
the UK. This is the largest study of its kind in the UK to date documenting current 
practices in the management of IC and its associated risk factors. From an 
analysis of baseline data we discovered that male sex and increasing age impart 
a high risk for developing PAD, as previously reported in other studies. Patients 
with bilateral claudication are also more likely to have significantly less absolute 
exercise tolerance as compared to unilateral claudicants. ABPI was found to 
have a significant association with angina, BMI, initial and absolute claudication 
distances and total cholesterol. We have discovered that patients with PAD are 
under treated for their risk factors as compared to those with prior or coexistent 
coronary or cerebrovascular disease. We have found that one quarter of 
claudicants were not on antiplatelet therapy at referral from the General 
Practitioner and those with a past history of CAD or lipid lowering or anti- 
hypertensive therapy were more likely to receive anti-platelet agents. Cholesterol 
levels were not checked in 9 of the 23 centres and the management of this risk 
factor was quite erratic. Many of the patients with significantly higher levels of 
cholesterol were not receiving any treatment at the initial visit. Similarly anti- 
hypertensive treatment appeared unsatisfactory as 13% of patients had 
inadequately controlled hypertension and 6% of the patients needed further 
assessment of their high blood pressure. Effective communication is required in 
this regard between the specialist vascular team and the referring General 
Practitioner. Surprisingly risk factor profiles and management of diabetics in our 
series was not much different as compared to non-diabetic claudicants. Again 
progression of the disease in this group was similar to the rest of the population 
at six months. 
A worryingly high proportion of claudicants were found to be smokers and 
disappointingly the smoking cessation rate was low at six-month follow up. The 
prevalence of smoking was much higher in the male population especially the 
younger age group. HDL levels were also found to be significantly lower in this 
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group. These two factors may partially be responsible for the increased incidence 
of IC among the males. 
Although we found a higher serum cholesterol levels among the females, the TC: 
HDL ratio was also higher as compared to the males. We did not find any 
difference in terms of management or progression of claudication in relation to 
gender as has been suggested by some other reports. 
Certain age related differences were noted which may have further clinical 
implications. We report that the younger population is less likely to be treated for 
their adverse risk factors as compared to the elderly or those with past history of 
cardiovascular disease. Younger claudicants were also found to be smoking 
currently in the majority of cases. Understandably the proportion of these current 
smokers decreased with age. Younger smokers were more likely to attempt to 
stop smoking as compared to the elderly; however, we feel that this group was 
not provided with enough smoking cessation support. Moreover, younger 
patients also had a higher serum cholesterol and TC: HDL levels as compared to 
the elderly; hence emphasising the need to check the lipid profile in all the 
patients. 
At six months follow up certain improvements were noted. These were not only in 
clinical parameters but also in terms of risk factor management. Improvement in 
relation to claudication distance at six months was across the board irrespective 
of age group or gender contrary to some earlier reports. A satisfying element of 
the six-month follow up was the significant improvement in the use of statins and 
antiplatelets. 
The overall pattern of management varied among different centres. Relatively 
higher numbers of patients underwent various forms of imaging and thus 
subsequent interventions as expected. This related more to the local practice 
pattern than the national management trends. Low ABPI and pack years smoked 
had a significant correlation with peripheral intervention. Again low ABPI was 
significantly associated with development of all vascular events along with the 
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high systolic pressure and history of CHD. Further morbidity and mortality rates 
were in line with the reported literature. 
Patients with IC are two to three times more likely to develop a fatal cardiac 
event than non-claudicants. We feel that a national risk factor management 
protocol or guidelines should be established. The current delivery of risk 
modifying interventions has been found to be very patchy. This was certainly the 
case at the initial visit when patients were referred from primary care. However at 
six month follow up we observed a significant improvement in the use of lipid 
lowering therapy and antiplatelets over a six month time period. Creating 
increasing awareness and education programmernes especially at the primary 
care level for the prevention and treatment of risk factors will go a long way in 
reducing further local and cardiovascular events. Besides the involvement of 
General Practitioners, perhaps nurse led risk factor clinics in the community may 
prove helpful in this regard. 
As many of the risk factors in PAD are common with those of CAD and CVD, 
establishment of risk lowering strategies "under one roof" would be a logical way 
forward. We believe that establishing national guidelines will enhance this 
benefit. "Risk lowering clinics* have been established in a few peripheral vascular 
centres already. Such an initiative is also needed at the national level. In a few 
countries like USA and Sweden such clinics have been established and provide 
a comprehensive risk factor lowering strategy and help in all aspects of PAD. 
These clinics, besides the diagnosis and management of treatable risk factors, 
should also have the facilities for the support of smoking cessation and 
supervised exercise programmes. Physicians, nurse practitioners, registered 
nurses, exercise physiologists, behavioural scientists, dieticians and social 
workers should staff or be involved in these clinics. Lifestyle modification also 
needs maximal support from relatives, friend and the community besides the 
therapist. This will require education of the public about PAD. Cost benefits in 
terms of reduction of future vascular events also need to be documented. 
It is recommended that a national database of risk factors in patients with IC 
should be established and the outcomes in relation to particular risk factors 
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should be analysed. Such an outcome can be reached by extension of the 
present study over a longer period of time. This may also help to establish a 
'vascular risk factor score' in relation to outcome in each patient. It is important to 
point out the group of patients that is likely to be at a higher level of risk of 
progression of disease. Such a score may become an effective tool in pinpointing 
this group of patients, as this will portray not only the severity of the disease 
process but also its prognosis. Perhaps a preventive strategy can be established 
in these patients on the basis of their risk factor profile. 
Using the present template, in an extension to the current PIRPARED study, data 
is also being collected to analyse the health costs of PAD at present in the UK. It 
will be interesting to see the effect of cost benefits of employing a uniform 
strategy for the management of PAD in the UK. This data can also differentiate 
the cost effectiveness of different modalities of treatment and interventions. This 
economic evaluation can relate the costs of a diagnostic or therapeutic strategy 
to its outcomes. 
The clinical outcome of treatment does not directly correlate with QoL outcomes. 
An optimal interventional result represents a step toward the achievement of an 
improved functional status, but it is not indicative of an overall improvement in the 
patient's QoL. Agreed QoL parameters should also be used to assess the 
outcome of procedures or treatment on the patient. 
Little has been done to study the effect of various modalities of treatment of PAD 
in IC in relation to QoL indicators. Randomised controlled studies to quantify 
these effects would help to determine the future direction of treatment of these 
patients. 
Data from this study documents the patient characteristics, current trends of 
management in terms of risk factors and the disease specific treatments and 
marks out the high risk factors in relation to specific subgroups. This data could 
help to focus the treatment to a specific target population in relation to their risk 
factor status or disease state. The current deficiencies highlighted above may 
help determine new benchmarks to improve future practice. Resources will have 
to be mobilised in order to meet these objectives. General practitioners are at the 
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forefront of any primary prevention. It is worrying that in the current new GMS 
contract for General Practitioners there are no points concerning the primary 
management of PAD. There is an urgent need to rectify this. 
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APPENDIX 1: Centres participated in the study. 
Institution Consultant Co-ordinator 
Aberdeen Royal Infirmary Ms Brittenden 
Addcnbrookcs Hospital %, Ir Varty Cathy Pitman 
Belfast City Hospital Mr Hannon Kathy McGuigan 
Birmingham I Icartlands I lospital Pro f Brad burv Yvonne I fall 
Dcrriford Hospital Mr Ashley Chryz Cosgrove 
Faling I lospital Mr Geroulakos Stella Daskalopou 
Freeman I lospital Prof Stansby Shiela Dugdill 
Frinilcy Park I lospital N1r Gerrard Claire King 
Gloucestershire Royal Hospital Mr Earnshaw Donna Parkin 
Gýwnt I Icaltlicarc NI IS Trust NIr Blackett Jayne Warren 
I full Royal Infirmary ProfMcCollurn Jenny Bryce 
ipsxý Ich I lospital Mr Osman Katic Weedon 
f. cicestcr Royal Infirmary Prof London 
Morriston I lospital Mr Gibbons Rachel I larvard 
Pindcrficlds I lospital Mr Curley 
Q1jccn 1.1lizaholl I lo"pital Mr 11hattacharya Marcus Cicanthis 
Royal Bournemouth I lospital Mr Parvin Sara Baker 
Royal Frec I lospital Mr Baker Phyl Morris-Vincent 
Royal (ýnitcd I lospital Prol'I lorrocks Tulin Bodarnyali 
SclIv ()ak I lospital Mr Vollra Chris Lee 
Southampton General I lospital Prot'Shearman Jenny Williams 
St Marý sI lospital Mr Cheshire Loulse Williams 
Walsgrave I lospital Mr I lignian Carol Bick 
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APPENDIX 2: Case Record Form (CRF) 
PATIENT DETAILS 
I First name 
2 Middle name 
3 Surname 
4 Hospital Number 
Ir Gender 
6 Date of Birth 
7 Telephone number 
DETAILS OF RELATIVE NOT AT THE SAME ADDRESS 
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PATIENT DETAILS 
I Initials (first, last) 
2 Date of birth 
3 Sex Male Fernale 
ý[] 
4 Date of visit 
. 5% 
Height crn 
6 Weight kg 
7 Resting heart rate bprn 
8 Systolic blood pressure mmHg 
9 Diastolic blood pressure mmHg 
10 Ethnic origin '- 
INCLUSION CRITERIA 
III listory ofintermittent arterial claudicatiotfl 
12 New ret'erral tO VaScular clinicý" 
13 Ability to provide written informed consent 
14 Ankle/brachial blood pressure index :ý0.9/1 
EXCLUSION CRITERIA 
is Critical limb ischaemia" 
16 Spinal canal claudication probable 
17 Claudication probably related to venous obstruction 
is Other acute major medical/surgical condition ý' 
19 Patient taking part in any other studies 
Caucasian Afro-Carribean 
East-Asian South Asian 
African Other 
specify 
Yes No slop 
No 
Yes No 
Yes No slop 
ýf No tit) not include this patient 
Yes [ loop No II 
Yes [ stop N( 
- 
Yes stop N-- 
] 
0 
Yes stop N 
Yes stop No 
If Yes do not inchide this patient 
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BASELINE MEDICAL HISTORY 
I Treatment for hypertension 
2 Treatment for hyperlipidaernia 
3 Angina" 
4 Diabetic"t 
-5 
Prior MI' (if yes date [mm/yyyyj) 
6 Prior CVA (if yes date [mm/yyyyl) 
7 Prior CABG (if yes date [mm/yyyy]) 
8 Prior PTCA'l (if yes date [mm/yyyy]) 
Yes No 
Yes No 
Yes No 
NIDD IDD [] 
Yes [ 
- 
/- 
--- 
No[ 
- - 
Yes[ No[ 
Yes[ No[ 
Yes[ No[ 
PERIPHE RAL VASCULAR DISEASE HISTORY 
9 Claudication bilateral 
10 Fstimated initial claudication distance 
Fstimated absolute claudication distance, 
12 Ankle brachial pressure index - Leftý' 
13 Ankle brachial pressure index - Right" 
14 Previous peripheral vascular graft" 
Is Known internal carotid stenosis (>50%)'2 
16 Aortic aneurysm"' 
17 1 las it treadmill Doppler test been carried out " 
----Yes 
No 
Yes No 
Yes No 
Yes No 
Yes No 
EMPLOYMENT AND EDUCATION HISTORY 
Is patient currently in paid employment 
I t'Yes, give average hours worked 
21) I)id c(lucation continue post minimurn school leaving age 
21 Dcgreeýequlvalent prollessional qualification 
Yes No 
Hours per week 
Yes No 
Yes No 
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SMOKING STATUS 
Smoking history' 
2 
3 
a) Current [i Go to Q3 
b) Ex-smoker Go to Q2 
c) Non-smoker Go to Q8 
d) Smoker other Go to Q4 
If ex-smoker, date stopped (mm/yyyy) 
Pack years smokedT 
If other, please give total amount smoked/weeký' NA 
Has patient attempted to stop in last 6 months Yes No NA 
If Q5 is Yes, please specify method used 
7 If Other please specify 
BLOOD TESTS 
8 Total Cholesterol 
9 HDL 
10 LDL 
II Triglycerides 
12 Glucose 
13 Creatinine 
14 llaernoglobin 
Is MCv 
16 Platelets 
17 White cell count 
IN CRP 
19 Fibrinogen 
211 1 lornocysteine 
a) Nicotine replacement therapy 
b) Bupropin (Zyban) 
c) Counselling 
d) Other 
inmol/L NA 
ini-nol/L NA 
inmol/L NA 
intliol/L NA 
inmoi/L NA 
umoll. NA 
g/dL NA 
flL NA 
10 9 /L NA 
109/L NA 
nio/L t> NA 
1 
- 1 
g/L NA []1 
- 
utnol/L NA f1 
7 
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I ANTIPLATELET MEDICATIONS 
Is patient taking an,,. antiplatelet medication- II 
If Yes, specify agent 
If taking aspirin, average daily dose 
1 t'Q I is No, please give reason 
51f Other, please specify 
OTHER MEDICATIONS 
hpid lm%cring (statin) 
1 ipid loý%ering (other) 
8 Warfarin/t 
Digoxin 
10 A(T, inhibitor 4 
II Boa blocker4 
12 Calcium antagonist 
13 Angiomisin 11 antagonist 
FOLLOW-UP DETAILS 
Yes No[ 
Yes ýýo [ 
Yes No[ 
L Yes No I 
Yes No fI 
Yes No[ 
Ycs No[ 
Ye's II Nol I 
21 1-. LiroQol, completed (il'yes date) 
22 PVD Qol. completed (if yes date) 
23 VascuQol. completed (il'yes date) 
24 1 FQ2 1-23 is No, please give reason 
25 Name ol'person completing CRF 
25 Date CRF completed 
26 Datc of planned lollow-up -' 
Yes [ ]gotoQ2 No ]go to Q4 
a) Aspirin Yes f No 
b) Clopidogrel Yes [ No 
c) Ticlopidine Yes [ No 
d) Dipyridaniole Yes [ No 
mg 
a) History of ulcers 
b) Indigestion 
C) Allergy 
d) Aspirin never prescribed/recommended 
e) Non-compliance 
f) Other 
14 Nitrate (oral/patch) Yes[ ýTq 
IS Vasodilator' Yes[ KOT 
16 Quinine Yes No[ 
17 Diuretic Yes 
Is Oral hypoglycaernic Yes 
19 Insulin Yes 
20 11 R'1*1 Yes 
14 Nitrate (oral/patch) 
Is Vasodilator' 
16 Quinine 
17 Diuretic 
I'leaw clicck this form carefull ,N 
and complete any missing data. The top copy of these pages along 
%ith file Completed que%liolillaires should be sent to the CTE U using the labels provided within 2 
da) % of (lie patient being enrolled into the study 
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6 MONTH FOLLOW-UP 
1 Date of follow-up 
I 
2 Method of follow-up 
I 
Hospital visit Telephone 
3 Weight kg 
4 Resting heart rate 
ýbprn 
.5 
Systolic blood pressure 
--- 
mmHg 
6 Diastolic blood pressure 
--- 
mmlig 
7 Claudication bilateral ' Yes I No 
8 Estimated initial claudication distanceT M 
9 Estimated absolute claudication distance' M 
10 Ankle brachial pressure index - Left'ý 
II Ankle brachlid pres,, ure index - Righfl 
ANTIPLATELET MEDICATIONS 
12 Is palictit taking any antiplatcIct medication' Yes [I go to Q13 No [I oo to QI 5 
13 IfYes, specify agent a) Aspirin Yes 10 
b) Clopidogrel Yes 10 
c)'Ficlopidine Yes 10 
d) Dipyridamole Yes 10 
14 ll'taking aspirin, average daily dose 
ALL MEDICATIONS 
I 
____ __ 
nig 
Lipid lowering (statin) 
L'6es 
No[ 23 Nitrate (oral/patch) Yes[ No 
16 Lipid lowering (other) Yes[ 
- 
No[ 24 Vasodilatorý 
17 Warfarin' Yes No 25 Quinine 
Is Digoxin Ye s N 26 Diuretic Yes No 
11) ACI. inhibitor Yes No 27 Oral hypoglycaernic Yes No 
20 Beta blocker" Yes IN ojl 1 28 Insulin Yes No[] 
21 Calcium antagonist Yes No[ 21) IIRT' Yes[] No 
22 Angiotcnsm 11 antagonist Yes No 
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EVENTS SINCE ENROLMENT 
II ias patient died (if yes date) Yes ---- 
No 
2 If ý es give main cause of death 
3 MI (if yes dateý Yes[ ---- 
No[ 
Yes[ No[ 
a) Haernorrhaggic 
b) Non-haernorrhagic 
c) Not known 
a) Major 
b) Minor 
c) Full recovery 
Yes[ No[ 
---- 
No[ 
---- 
No[ 
-YesMajor[ 
I Yes, Minor No[ 
_ 7 
. 
Yes No[ 
NA [ 
: 
1] 
Yes 
---- 
No[ 
CVA (ifýes date) if No, go to Q7' 
5 Type of CVA 
Level of disability 
TIA(if yes date)ý' 
8 Coronary angioplasty(if yes date)' 
9 CABG (if yes datef 
10 11criplicral arterial revascularisation " 
II If yes give date 
12 Congestive heart failure (if yes datey^' 
13 Last known creatinine and date performed 
14 Was diaksis required date)"' Yes --- 
No 
L OTHER HOSPITAL ADMISSIONS SINCE ENROLMENT 
-5 
1 lopliallsation tor other reason Yes No 
16 1 f'yes, reason for admission I NA[ 
17 1 l'yes, reason for admission 21 NA [II 
is I I'vcs, reason lor admission 3L NA 
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SMOKING STATUS 
I 
2 
3 
7 
PATIENT'S SYMPTOMS 
If Other please specify 
Compared to the time of first recruitment into the study 
have the patient's symptoms 
9 
Smoking history' a) Current Go to Q3 
b) Ex-smoker Go to Q2 
c) Non-smoker Go to Q8 
d) Smoker other Go to Q4 
If ex-smoker, date stopped (mm/yyyy) 
Pack years smoked It 
if other, please give total amount smoked/weeký' 
Has patient attempted to stop in last 6 months 
IfQ5 is Yes, please specify method used 
Similarly has the patient's ability to mobilise (with 
respect to his or her peripheral arterial disease) 
Yes No NA 
a) N icotine replacement therapy 
b) Bupropin (Zyban) 
C) Counselling 
d) Other 
I 
a) Improved substantially 
b) Improved slightly 
c) Not chanoed 
d) Deteriorated Slightly 
e) Deteriorated substantially 
a) Improved substantially 
b) Improved slightly 
c) Not changed 
d) Deteriorated slightly Z. ý I 
e) Deteriorated substantially 
f) Deteriorated for reasons other than PAD 
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FOLLOW-UP DETAILS 
I EuroQoL completed (if yes dater 
2 PVD QoL completed (if yes dater 
3 VascuQoL completed (if yes dater 
4 If Q1 -3 is No, please give reason 
Is Name ofperson completing CRIF 
6 Date CRIF completed 
7 Date of planned follow-upý 
INVESTIGATORS DECLARATION"' 
By signing below, I declare that the information presented in this Case Record Form 
accitratety reflects the medical records, including the results of tests and evalitations 
performed on the (Ititesspecifted. 
8 Date 
9 Name of investigator 
10 Signature of investigator 
Please check this form carcfully and complete any missing data. The top copy of these pages along with 
the completed q ues( ion nai res should be sent to the Clinical Trials and Evaluation Unit, Royal Brompton 
I lospital using the labels provided within 2 days of this visit 
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APPENDIX 3: Euroqol -5 Questionnaire 
Please indicate which statement best describes your own health today. 
I Mobility 
I have no problems walking about 
El 
I have some problems in walking about 
I am confined to bed 
2 Self care 
I have no problems with self-care El 
I have some problems washing or dressing myself El 
I am unable to wash or dress myself 11 
3 Usual activities (e. g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities 
El 
I have some problems with performing my usual activities 
El 
I am unable to perform my usual activities 
13 
4 Pain / Discomfort 
I have no pain or discomfort 
El 
I have moderate pain or discomfort 
11 
I have extreme pain or discomfort 
El 
6 Anxiety/ Depression 
I am not anxious or depressed El 
I am moderately anxious or depressed 11 
I am extremely anxious or depressed El 
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Your own health state today 
Best 
To help people say how good or bad t1wr ImaginaMe 
health state Is, we have drawn a scale health state 
(raOw Ike a Vwmometer) on wNch the 100 
best state you can imagine Is marked by 
100 and to worst state you could Imagine 
is marked by 01- 
We wotAd like You to indicate on 0* scale 
how good or bad your own health Is today, 
In your opinion. Please do Ns by drawing 
a fine from the box to whidwm point on 
the scale Indicates how good or bad your 
current health state Is. 
I Your own 
health state 
today 
I 
worst 
Imaginable 
health state 
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APPENDIX 4: Peripheral Artery Questionnaire 
The Peripheral Arterial Questionnaire 
The following questions refer to blockages in the arteries of your body, particularly your 
legs, and how that might affect your life. Please read and complete the following 
questions. There are no right or wrong answers. Please mark the answer that best applies 
to you. 
1. Blockages in the arteries, often referred to as peripheral vascular disease, affect 
different people in different ways. Some feel cramping or aching while others feel 
fatigue. Which leg (or buttock) causes you the most severe discomfort, fatigue, pain, 
aching, or cramps? 
the Right leg (buttock) the Left leg (buttock) Both are the same Neither 
0 11 11 1: 1 
2. Please review the list below and indicate how much limitation you have due to your 
peripheral vascular disease (discomfort, fatigue, pain, aching, or cramps in your 
calves (or buttocks)) over the past 4 weeks. 
Place an X in one box on each line 
Limited for other 
Activity 
Extremely Quite a bit Moderately Slightly Not at reasons or did not Limited Limited Limited Limited all 
do the activity 
Limited 
Walking around El 11 1-3 11 your home 
Walking 1-2 blocks 
El El El El El on level ground 
Walking 1-2 blocks 
up a hill El El El El El El 
Walking 3-4 blocks 
on level ground El El 1: 1 El 
Hurrying or jogging 
(as if to catch a bus) 
Vigorous work or 
exercise 
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3. Compared with 4 weeks ago, have your symptoms of peripheral vascular disease 
(discomfort, fatigue, pain, aching, or cramps in your calves (or buttocks)) changed? 
My symptoms have become 
Much Slightly Not Slightly Much 
worse worse changed better better 
00000 
I have had no 
symptoms over the 
past 4 weeks 
0 
4. Over the past 4 weeks, how many times did you have discomfort, fatigue, pain, 
aching, or cramps in your calves (or buttocks)? 
All of Several At least 3 or more times 1-2 times Less than once Never over 
the time times per once a day per week but not per week a week the past 4 
day every day weeks 
11 11 11 11 11 1: 1 11 
S. Over the past 4 weeks, how much has discomfort, fatigue, pain, aching, or cramps 
in your calves (or buttocks) bothered you? 
It has been... 
Extremely Moderately Somewhat Slightly Not at all I've had no leg 
bothersome bothersome bothersome bothersome bothersome discomfort 
El 11 11 11 11 11 
6. Over the past 4 weeks, how often h, 
cramps in your legs or feet? 
3 or more times 
Every night per week but not 
every night 
ive you been awakened with pain, aching, or 
1-2 times Less than once Never over 
per week a week the past 4 
weeks 
7. How satisfied are you that everything possible is being done to treat your peripheral 
vascular disease? 
Not satisfied Mostly Somewhat Mostly Completely 
at all dissatisfied satisfied satisfied satisfied 
1: 1 11 11 11 11 
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8. How satisfied are you with the explanations your doctor has given you about your 
peripheral vascular disease? 
Not satisfied Mostly Somewhat Mostly Completely 
at all dissatisfied satisfied satisfied satisfied 
00 0 0 0 
9. Overall, how satisfied are you with the current treatment of your peripheral vascular 
disease? 
Not satisfied Mostly Somewhat 
at all dissatisfied satisfied 
00 0 
Mostly Completely 
satisfied satisfied 
00 
10. Over the past 4 weeks, how much has your peripheral vascular disease limited your 
enjoyment of life? 
It has It has limited my It has moderately It has slightly It has not limited my 
extremely enjoyment of life limited my limited my enjoyment of life at 
limited my quite a bit enjoyment of life enjoyment of life all 
enjoyment 
of life 
13 11 11 11 11 
1. If you had to spend the rest of your life with your peripheral vascular disease the 
way it is right no , 
how would you feel about this? 
Not at all Mostly Somewhat Mostly Completely 
satisfied dissatisfied satisfied satisfied satisfied 
00000 
12. Over the past 4 weeks, how often have you felt discouraged or down in the dumps 
because of your peripheral vascular disease? 
I felt that way I felt that way I occasionally I rarely felt that I never felt that 
all of the time most of the time felt that way way way 
000 
164 
0 0 
13. How much does your peripheral vascular disease affect your lifestyle? Please 
indicate how your discomfort, fatigue, pain, aching, or cramps in your calves (or 
buttocks) may have limited your participation in the following activities over the past 
4 weeks. 
Please place an X in one box on each line 
Does 
Activity Severely Limited Moderately Slightly Did not not 
limited quite a bit limited limited limit at all apply or 
did not 
do for 
other 
reasons 
Hobbies, 
recreational 
activities 
Visiting 
family or 
friends out of 
your home 
Working or 
doing 
household 
chores 
14. If you have wanted to have sexual relations, how much difficulty have you had in 
doing this over the past 4 weeks? 
It has been.... 
Extremely Moderately Somewhat 
difficult difficult difficult 
Slightly Not at all I have not had or 
difficult difficult wanted to have 
sexual relations 
0 11 0 000 
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APPENDIX 5: Information Sheet for Patients 
Title of project: 
(PREPARED-UK) Prospective Registry and Evaluation of Peripheral Arterial 
Risks, Events and Distribution in the UK 
Invitation to participate: 
You are being asked to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
involves. This information sheet is designed to help you decide whether you 
would like to participate in this study. Please take time to read the following 
information carefully and discuss it with friends, relatives and your GP if you 
wish. Please ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
What is the purpose of the study and why have I been chosen? 
You have been referred to this hospital because you are suffering from 
Peripheral Arterial Disease (PAD). This is both a common and important 
condition. The purpose of this letter is to ask for your permission to use 
information about your medical condition for a registry study. A registry study 
records information on patients medical history and treatments, it does not 
change your medical care in any way. This study will be carried out in about 
25 hospitals throughout the country and will document a few important medical 
details of patients like yourself. This will provide valuable information to help 
doctors understand more about peripheral arterial disease and will guide future 
research to improve the treatment of patients with these conditions. 
Do I have to take part 
No, you do not have to take part. It is up to you whether or not to take part. If 
you do decide to take part you will be given this information sheet to keep and be 
asked to sign a consent form. If you do decide to take part you are still free to 
withdraw at any time and without giving a reason. This will not affect the 
standard of care you receive. 
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What will happen to me if I take part? 
We will record information about your medical condition, this data will be 
recorded anonymously. We would expect this to take less than one hour. 
Participation in this study will have no effect on the care you receive at any 
time. You will not undergo any extra tests or receive any extra treatments as a 
result of this study, and most of the information will be obtained from your 
medical records. Brief details of your state of health 6 months after you agree 
to take part need to be recorded. This can either be done at a routine clinic 
appointment or by telephone. We may contact you again up to 2 years after 
you agree to take part to see how you are and what, if any, new medical 
problems you have had. Longer term follow-up is important because it 
provides valuable information about the effects of peripheral arterial disease 
on your health status over a number of years. We will also ask you to 
complete 2 short questionnaires which ask questions about your quality of life 
at each visit. 
We will write to your GP to inform them that you are taking part in this study. 
We will also continue to gather some very limited information about your health 
in the longer term. This may be for up to twenty years after your enrolment into 
the study and will not involve us contacting you in any way. This is done by a 
process called 'flagging' which involves giving your name to the Office of 
National Statistics (they also collect the information in the UK census). This 
process does not involve you in any extra contact with your hospital or with 
doctors. The information given to the Office of National Statistics (name, 
address and NHS number) is kept strictly confidential and they will not contact 
you or your family directly. 
What are the possible benefits of taking part? 
You are unlikely to benefit directly from participation in this study, however, any 
knowledge gained from your taking part is likely to be of benefit to others. The 
results of this study will be used to improve future treatments and care for 
patients like you. 
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Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will 
be kept strictly confidential. Information collected will not be used for any other 
purpose than that explained in this explanation. 
What happens to the results of the research study? 
The main findings of this registry will be submitted for publication in prominent 
journals and presented findings at scientific meetings. They will be used as a 
standard by which future practice may be improved. If you wish to obtain a copy 
of the results you should contact the research co-ordinator when the research is 
completed (after July 2003). You will not be identified in any reports or 
publications arising from this research. 
Who is organising and funding the research? 
This study is being organised and co-ordinated by the Clinical Trials and 
Evaluation Unit at the Royal Brompton Hospital in London and the Northern 
Vascular Unit at the Freeman Hospital in Newcastle. Your doctor will be paid a 
small amount for including you in this study. 
Who has reviewed the study? 
The Multi Centre Research Ethics Committee have reviewed and approved this 
study. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled "Medical 
Research and You. " This leaflet gives more information about medical research 
and looks at some of the questions you may want to ask. A copy may be 
obtained from CERES, PO Box 1365, London, N16 OBW. 
Thank you for taking the time to read this information sheet. The doctors and 
nurses involved in this study will be pleased to discuss any questions or 
concerns that you may have. If you have any further questions about this 
research please contact your consultant at the address provided. 
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APPENDIX 6: Consent Form 
Centre Number: 
Study Number: 
Patient Identification Number for this trial: 
CONSENTFORM 
Title of Project: 
PREPARED UK. Prospective Registry and Evaluation of Peripheral Arterial 
Risks, Events and Distribution in the UK 
Name of Researcher: 
Please initial box 
1.1 confirm that I have read and understand the information sheet dated 8 th 
August 2002 (version 6) for the above study and have had the opportunity to ask 
questions. El 
2.1 understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. El 
3.1 understand that sections of any of my medical notes may be looked at by 
responsible individuals from Clinical Trials and Evaluation Unit, Royal Brompton 
Hospital or from regulatory authorities where it is relevant to my taking part in 
research. I give permission for these individuals to have access to my records. 
D 
4.1 agree to take part in the above study. 
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5.1 give consent for my details to be sent to the Office of National Statistics and 
for this information to be accessed for up to 20 years for the purposes of this 
study only. El 
6.1 give consent for my GP to be informed of my participation in this study 
D 
Name of Patient 
Signature 
Name of Person taking consent Date 
(if different from researcher) 
Date 
Signature 
Researcher Date 
Signature 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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